document incorporate reference document proxy statement annual meeting shareholder hold iii file securities exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum afinancial statement note consolidated financial statement report independent register public accounting firm bsupplementary datum item change disagreement accountant account financial disclosure item control procedure management report item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule signature table content item business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health alliance healthcare service segment pharmaceutical segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer merck alliance segment primarily include result company relationship astrazeneca termination relationship june companys healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient october company divest consumer care segment develop manufacture market overthecounter foot care sun care product company incorporate new jersey financial information information company segment item management discussion analysis financial condition result operation item financial statement supplementary datum product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner product sale sale company pharmaceutical product total sale animal health product follow million total sale pharmaceutical januvia zetia janumet gardasilgardasil remicade isentress proquadmmr iivarivax vytorin cubicin singulair animal health consumer care revenue october company divest consumer care segment develop manufacture market overthecounter foot care sun care product revenue primarily comprise miscellaneous corporate revenue include revenue hedging activity thirdparty manufacture sale table content pharmaceutical company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder certain product company franchise follow primary care women health cardiovascular zetia ezetimibe market ezetrol country outside united states vytorin ezetimibesimvastatin market inegy outside united states cholesterol modifying medicine diabete januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabete general medicine women health nuvare etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshape subdermal contraceptive implant dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate combination medicine treatment asthma follistim follitropin beta injection market puregon country outside united states fertility treatment hospital specialty hepatitis zepatier elbasvir grazoprevir approve food drug administration fda january treatment adult patient chronic hepatitis virus hcv genotype infection ribavirin pegintron peginterferon alphab victrelis boceprevir medicines treatment chronic hcv hiv isentress raltegravir hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection hospital acute care cubicin daptomycin injection antibiotic complicated skin skin structure infection bacteremia cause designate susceptible organism cancida caspofungin acetate antifungal product invanz ertapenem sodium treatment certain infection noxafil posaconazole prevention invasive fungal infection bridion sugammadex injection medication reversal type neuromuscular block agent surgery primaxin imipenem cilastatin sodium antibacterial product immunology remicade infliximab treatment inflammatory disease simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease company market europe russia turkey oncology keytruda pembrolizumab treatment advanced melanoma metastatic nonsmallcell lung cancer nsclc patient tumor express pdl disease progression follow therapy emend aprepitant prevention chemotherapyinduce postoperative nausea vomit temodar temozolomide market temodal outside united states treatment certain type brain tumor diversify brand respiratory singulair montelukast medicine indicate chronic treatment asthma relief symptom allergic rhinitis nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptom clarinex desloratadine nonsedate antihistamine cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatments hypertension arcoxia etoricoxib treatment arthritis pain company market outside united states fosamax alendronate sodium market fosamac japan treatment prevention osteoporosis zocor simvastatin statin modifying cholesterol propecia finasteride product treatment male pattern hair loss table content vaccine gardasil human papillomavirus quadrivalent type vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccine help prevent certain disease cause certain type human papillomavirus hpv proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella mmr measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella zostavax zoster vaccine live vaccine help prevent shingles herpe zoster rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease animal health animal health segment discover develop manufacture market animal health product include vaccine principal product segment include livestock product nuflor antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine bovine swine antiinflammatory estrumate treatment fertility disorder cattle matrix fertility management swine resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo bovine respiratory disease zilmax revalor improve production efficiency beef cattle safeguard dewormer cattle mpac swine pneumonia vaccine porcilis circumvent vaccine line infectious disease swine poultry product nobilisinnovax vaccine line poultry paracox coccivac coccidiosis vaccine companion animal product bravecto chewable tablet kill flea tick dog week nobivac vaccine line flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabetes mellitus treatment dog cat panacursafeguard broadspectrum anthelmintic dewormer use animal regumate fertility management horse prestige vaccine line horse activylscaliborexspot protect bite flea tick mosquitoe sandfly aquaculture product slice parasiticide sea lice salmon aquavacnorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor antibiotic farmraised fish discussion sale company product item management discussion analysis financial condition result operation product approval january merck announce fda approve zepati treatment adult patient chronic hcv infection ribavirin december merck announce fda approve expand age indication gardasil mercks valent hpv vaccine include use male year age prevention anal cancer precancerous dysplastic lesion genital wart cause certain hpv type gardasil include great number hpv type available hpv vaccine december company announce fda approve expand indication keytruda antipd program death receptor therapy include firstline treatment patient unresectable metastatic melanoma additionally fda approve update product label keytruda treatment patient ipilimumabrefractory advanced melanoma october fda grant accelerated approval keytruda dose mgkg week treatment patient metastatic nsclc tumor express pdl determine fdaapprove test disease progression platinumcontaine chemotherapy patient egfr alk genomic tumor aberration disease progression fdaapprove therapy aberration prior receive keytruda addition approve keytruda nsclc fda approve companion diagnostic enable physician determine level pdl expression patient tumor table content september merck announce japanese pharmaceutical medical device agency approve marizev omarigliptin tablet oral onceweekly dipeptidyl peptidase dpp inhibitor indicate treatment adult type diabete japan country approve omarigliptin joint venture sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur form joint venture market human vaccine europe collaborate development combination vaccine distribution thenexiste european union european free trade association merck sanofi pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc spmsd joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributor rest territory license subsidiary scheringplough corporation scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company marketing right product europe russia turkey scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system european commission approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi follow receipt pricing reimbursement approval remicade lose market exclusivity major european market february company long market exclusivity marketing territory company continue market exclusivity simponi marketing territory profit derive merck distribution product country equally divide merck competition health care environment competition market company conduct business pharmaceutical industry general highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug manufacturer animal health care company companys operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent right increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect intangible asset associate certain product competitive pressure intensify pressure industry grow pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance license arrangement refine sale marketing effort address table content change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient backdrop united states enact major health care reform legislation patient protection affordable care act began implement insurance market reform advance state federal insurance exchange launch end decade law expect expand access health care million americans previously insurance coverage respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million million record merck reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual nontax deductible health care reform fee total annual industry fee billion remain billion fee assess company proportion share prior year brand pharmaceutical sale certain government program medicare medicaid company record million million million cost marketing administrative expense respectively annual health care reform fee high expense reflect final regulation annual health care reform fee issue internal revenue service irs july final irs regulation accelerate recognition criterion fee obligation year year underlie sale allocate fee occur year fee pay result change merck record additional year expense million january center medicare medicaid services issue medicaid rebate final rule implement provision patient protection affordable care act effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid programs merck evaluate rule determine material impact merck medicaid rebate liability company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care organization federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure example health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue generating cost saving proposal include additional direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation table content medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company effort health care cost containment remain intense european country country continue announce execute austerity measure include implementation pricing action reduce price generic patent drug mandatory switch generic drug company take step mitigate impact country austerity measure continue negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance addition majority country attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug brand authority use price data market set new local price brandname drug include company guideline examine reference pricing usually set local market change pursuant local regulation addition japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine occur furthermore government order repricing class drug determine appropriate applicable rule certain market outside united states implement cost management strategy health technology assessment require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement company focus emerge market increase government emerge market focus constrain health care cost enact price control relate measure compulsory license aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states time fda commit expedite development review product bear breakthrough therapy designation appears accelerate regulatory review process medicine designation table content adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment research development discussion regulatory approval process access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care addition company farreache philanthropic program merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccine merck launch merck mother longterm effort global health partner end preventable death complication pregnancy childbirth merck provide fund merck foundation independent organization partner variety organization dedicate improve global health privacy datum protection company subject significant number privacy datum protection law regulation globally place restriction company ability efficiently transfer access use personal datum business legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include new general data protection regulation effective impose penalty percent global revenue additional law regulation enact united states europe asia latin america increase enforcement litigation activity united states develop market increase regulatory cooperation privacy authority globally company adopt comprehensive global privacy program manage evolve risk certify compliant asia pacific economic cooperation crossborder privacy rule system regulatory review october court justice invalidated decision hold useu safe harbor framework safe harbor provide adequate protection transfer personal datum european economic area united states merck annually selfcertifie adherence safe harbor rely safe harbor significant number data transfer business november merck work regulatory recognition global privacy program meeting eus bind corporate rule requirement alternative legal mechanism internal company transfer end january review company bind corporate rule application complete member state participate mutual recognition process completion final cooperation review phase expect quarter bind corporate rule approval expect reduce operational impact safe harbor invalidation global business crossborder datum transfer party support company business directly facilitate bind corporate rule approve company anticipate standard global privacy program meet bind corporate rule review support ability comply new euus privacy shield transatlantic datum transfer agreement replace safe harbor announce february continue implement data transfer mechanism necessary support business table content distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company business patent trademark license patent protection consider aggregate material importance company marketing product united states major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant current patent law provide additional patent term patent term restoration period patent product regulatory review fda table content patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection include potential patent term restoration pediatric exclusivity indicate follow market product product year expiration invanz compound composition cubicin composition zostavax use dulera formulation combination zetiavytorin asmanex formulation nasonex formulation nuvare delivery system emend injection noxafil rotateq intron recombivax method makingvectors januviajanumetjanumet isentress bridion pende patent term restoration nexplanon device device applicator grastek use ragwitek use bravecto pende patent term restoration zontivity pende patent term restoration gardasilgardasil keytruda zerbaxa pende patent term restoration sivextro pende patent term restoration belsomra zepati compound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability december decision district court action hospira inc hospira june patent find valid infringe later patent cubicin expire september november find invalid november court appeals federal circuit cafc affirm low court decision hospiras application fda approve june early district court action teva result settlement teva launch generic version cubicin late december early certain condition event june agreement generic manufacturer launch generic version zetia united states december district court decision uphold appeal cafc find propose generic product apotex generic manufacturer infringe merck nasonex formulation patent apotexs application approve fda enter market united states generic version nasonex eligible month pediatric exclusivity expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset table content increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty company follow key patent protection drug candidate review united states fda additional patent term provide pipeline candidate base patent term restoration pediatric exclusivity currently anticipate review year expiration pediatric hexavalent combination vaccine method makingvector bezlotoxumab company follow key patent protection drug candidate phase development currently anticipate phase drug candidate year expiration inactivated varicella zoster virus vzv vaccine use ebola vaccine odanacatib letermovir allergy house dust mite use anacetrapib mka relebactam imipenemcilastatin omarigliptin verubecestat ertugliflozin mka ertugliflozin sitagliptin mkb ertugliflozin metformin doravirine mkb contraception generation ring note patent chart compound patent patent subject future patent term restoration year month pediatric market exclusivity available addition depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide effective long last marketing exclusivity compound patent estate united states data protection generally run year marketing approval new chemical entity extend seven year orphan drug indication year marketing approval biological product information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity research development expense billion billion table content billion include restructuring cost acquisition divestiturerelated cost year company prioritize research development effort focus candidate believe represent breakthrough science difference patient payer company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologic capability company commit make externally source program great component pipeline strategy renew focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company review pipeline examine candidate provide value outlicense company continue evaluate certain latestage clinical development platform technology asset determine outlicense sale potential company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease neurodegenerative disease osteoporosis respiratory disease women health development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include new drug application nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic molecule believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase trial design twostage trial design consist phase proofofconcept stage phase doseoptimization finding stage datum phase trial satisfactory company commence largescale phase trial confirm compound efficacy safety type adaptive clinical trial adaptive phase trial design study include interim analysis adaptation change trial feature common phase study multiple dose group design similar phase trial adaptive phase trial design reduce timeline eliminate activity require start separate study completion phase trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase study doserange study finally phase trial provide necessary datum effectiveness safety successful company submit regulatory table content filing appropriate regulatory agency stage propose manufacturing facility undergo preapproval inspection production vaccine progress examine detail united states fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review pursuant prescription drug user fee act pdufa fda review period target nda original bla month priority review month standard review time application deem sufficiently complete review timeline determine fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter crl state application approve present form describe deficiency fda identify company wish pursue application receive crl resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission fda program designation fast track breakthrough therapy accelerate approval priority review facilitate expedite development review new drug address unmet medical need treatment lifethreatening condition fast track designation provide pharmaceutical manufacturer opportunitie frequent interaction fda reviewer product development ability manufacturer roll submission ndabla rolling submission allow complete portion application submit review fda ongoing basis breakthrough therapy designation provide manufacturer feature fast track designation intensive guidance implement efficient development program product commitment fda involve senior manager experience staff review accelerate approval designation allow fda approve product base effect surrogate intermediate endpoint reasonably likely predict product clinical benefit generally require manufacturer conduct require postapproval confirmatory trial verify clinical benefit priority review designation mean fda goal action ndabla month compare month standard review addition generate antibiotic incentive act fda grant qualified infectious disease product qidp status antibacterial antifungal drug intend treat life threatening infection include cause antibiotic antifungal resistant pathogen novel emerge infectious pathogen qualify pathogen qidp designation offer certain incentive development qualify drug include priority review nda file eligibility fast track designation fiveyear extension applicable exclusivity provision food drug cosmetic act primary method company use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state outside united states company submit marketing application national regulatory authority examples pharmaceutical medical devices agency japan health canada agncia nacional vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia china food drug administration country separate independent review process timeline market approval time long regulatory authority require approval table content major market united states issuance certificate pharmaceutical product market initiate local review process research development update company currently candidate regulatory review united states internationally keytruda fdaapprove antipd therapy clinical development expand indication different cancer type keytruda currently approve treatment melanoma advanced melanoma nsclc december merck announce result pivotal keynote study evaluate potential immunotherapy compare chemotherapy base prospective measurement pdl expression patient advance nsclc phase study keytruda significantly improve overall survival compare chemotherapy patient level pdl expression base datum merck submit supplemental bla fda file maa ema november merck announce fda grant breakthrough therapy designation keytruda treatment patient microsatellite instability high metastatic colorectal cancer keytruda previously grant breakthrough therapy status advanced melanoma advanced nsclc keytruda clinical development program consist clinical trial include trial combine keytruda cancer treatment study encompass cancer type include bladder colorectal esophageal gastric head neck melanoma multiple myeloma non smallcell lung triple negative breast currently phase clinical development bezlotoxumab investigational antitoxin prevention clostridium difficile difficile infection recurrence currently review fda ema january merck announce fda accept review bla bezlotoxumab grant priority review pdufa action date july september merck announce pivotal phase clinical study bezlotoxumab meet primary efficacy endpoint reduction difficile recurrence week compare placebo conjunction standard care antibiotic treatment difficile company seek approval intend file canada currently therapie approve prevention recurrent disease cause difficile insulin glargine candidate treatment patient type type diabete develop collaboration samsung bioepis december company submit application regulatory approval plan submit fda mka zepatier currently review treatment chronic hcv oncedaily fixeddose combination tablet contain nsa inhibitor elbasvir nsa protease inhibitor grazoprevir zepatier approve fda january treatment adult patient chronic hcv infection ribavirin investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda develop approve commercialize partnership merck sanofi pasteur vaccine design help protect important disease diphtheria tetanus pertussis whooping cough polio poliovirus type invasive disease cause haemophilus influenzae type hib hepatitis november fda issue crl respect bla company review crl plan communication fda february grant marketing authorization prophylaxis diphtheria tetanus pertussis hepatitis poliomyelitis invasive disease cause hib infant toddler age week market vaxeli spmsd company joint venture sanofi pasteur addition candidate regulatory review company drug candidate phase clinical development addition keytruda program discuss company anticipate file application regulatory approval fda respect certain candidate include note odanacatib oral onceweekly investigational treatment patient osteoporosis osteoporosis disease reduce bone density strength result increase risk bone fracture table content odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis september merck announce datum pivotal phase fracture outcomes study odanacatib postmenopausal woman osteoporosis longterm odanacatib fracture trial loft odanacatib meet primary endpoint significantly reduce risk type osteoporotic fracture radiographicallyassesse vertebral clinical hip clinical nonvertebral compare placebo reduce risk secondary endpoint clinical vertebral fracture addition treatment odanacatib lead progressive increase year bone mineral density lumbar spine total hip rate adverse event overall loft generally balanced patient take odanacatib placebo adjudicate event morphea like skin lesion atypical femoral fracture occur odanacatib group placebo group adjudicate major adverse cardiovascular event generally balance overall treatment group numerically adjudicate stroke event odanacatib placebo adjudicate atrial fibrillation report odanacatib group placebo group numeric imbalance mortality observe numeric difference appear related particular reported cause cause death merck continue collect datum blind extension study plan additional analysis datum trial include independent readjudication major adverse cardiovascular event mace support regulatory submission merck plan submit nda fda odanacatib follow completion independent adjudication analysis mace merck plan submit application ema ministry health labour welfare japan omarigliptin investigational onceweekly dpp inhibitor development treatment adult type diabete september company announce omarigliptin achieve primary efficacy endpoint phase study omarigliptin find noninferior januvia reduce patient estimate person blood glucose twoto threemonth period level baseline similar reduction achieve group headtohead study design evaluate onceweekly treatment omarigliptin compare januvia daily result present oral session european association study diabete annual meeting september merck announce japanese pharmaceutical medical device agency approve marizev omarigliptin tablet japan country approve omarigliptin merck plan submit omarigliptin regulatory approval united states worldwide regulatory submission follow ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate treatment type diabete collaboration pfizer inc ertugliflozin study combination januvia sitagliptin metformin merck expect submit application regulatory approval united states ertugliflozin fixeddose combination tablet end investigational allergy immunotherapy tablet house dust mite allergy north america partnership merck alkabello merck plan submit nda fda half verubecestat merck novel investigational oral amyloid precursor protein sitecleave enzyme bace inhibitor treatment alzheimer disease study phase trial apec design evaluate safety efficacy versus placebo patient amnestic mild cognitive impairment alzheimer disease know prodromal alzheimer disease study phase randomize placebocontrolle study patient mildtomoderate alzheimer disease epoch epoch study complete enrollment fourth quarter estimate reach primary trial completion mid anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raise hdlc reduce ldl anacetrapib evaluate patient eventdriven cardiovascular clinical outcome trial sponsor oxford university reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease project conclude early november merck announce datum monitor committee dmc reveal outcomes study complete planned review unblinde study datum recommend study continue change dmc review safety efficacy datum study include assessment futility merck remain blind actual result analysis reveal safety efficacy datum table content reveal steer committee merck continue monitor progress study additional interim efficacy analysis plan mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approve carbapenem antibiotic fda designate combination qidp designate fast track status treatment hospitalacquire bacterial pneumonia ventilatorassociate bacterial pneumonia complicated intraabdominal infection complicate urinary tract infection letermovir investigational oral oncedaily antiviral candidate prevention treatment human cytomegalovirus infection letermovir receive orphan drug status united states grant fast track designation mkb refer generation ring investigational combination etonogestrel estradiol vaginal ring contraception treatment dysmenorrhea woman seek contraception mkj investigational fixeddose combination sitagliptin ipragliflozin development commercialization japan collaboration astellas pharma inc astella ipragliflozin sglt inhibitor codevelope astellas kotobuki pharmaceutical ltd kotobuki approve use japan copromote merck kotobuki investigational rvsvzebov ebola vaccine candidate study large scale phase clinical trial currently underway west africa november merck newlink genetic announce exclusive licensing collaboration agreement investigational ebola vaccine december merck announce application emergency use assessment list eual accept review world health organization accord eual process design expedite availability vaccine need public health emergency outbreak ebola procedure intend assist united nations procurement agency member state acceptability vaccine candidate emergencyuse set eual designation prequalification special procedure implement outbreak disease high rate morbidity andor mortality lack treatment andor prevention option instance recommend make vaccine available limited time clinical trial datum gather formal regulatory agency review national regulatory authority decision grant eual status base datum quality safety efficacyeffectiveness riskbenefit analysis emergency use eual designation allow emergency use vaccine remain investigational license commercial distribution inactivated varicella zoster virus vzv vaccine development prevention herpe zoster company conduct phase trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy doravirine investigational oncedaily oral nextgeneration nonnucleoside reverse transcriptase inhibitor develop merck treatment hiv infection company divest discontinued certain drug candidate july merck allergan plc allergan enter agreement pursuant allergan acquire exclusive worldwide right merck investigational small molecule oral calcitonin generelate peptide receptor antagonist develop treatment prevention migraine surotomycin investigational oral antibiotic development treatment difficile associate diarrhea merck acquire surotomycin purchase cubist second quarter company receive unfavorable efficacy datum randomize doubleblinde activecontrolled study patient difficile associate diarrhea evaluation datum combine assessment commercial opportunity surotomycin result discontinuation program bevenopran oral investigational therapy development potential treatment opioidinduce constipation patient chronic noncancer pain merck acquire bevenopran purchase cubist company decision continue development program seek outlicense asset table content corifollitropin alfa injection investigational fertility treatment control ovarian stimulation woman participate assist reproductive technology july merck receive crl fda nda corifollitropin alfa injection merck decision discontinue development corifollitropin alfa injection united states business reason corifollitropin alfa injection market elonva certain market outside united states chart reflect company research pipeline february candidate show phase include specific product date candidate enter phase development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation note candidate phase additional indication therapeutic area additional claim line extension formulation inline product show phase phase phase entry date review alzheimer disease allergy cancer house dust mite march keytruda asthma alzheimer disease nonsmallcell lung verubecestat december clostridium difficile infection cancer atherosclerosis bezlotoxumab useu keytruda anacetrapib diabete mellitus hodgkin lymphoma bacterial infection pmbcl primary mediastinal mka relebactamimipenemcilastatin hepatitis large bcell lymphoma october mka zepatier advance solid tumor cancer pediatric hexavalent combination vaccine keytruda bladder october diabetes breast october footnote colorectal november heart failure esophageal december develop collaboration vericiguat gastric north american right hepatitis head neck november investigational pediatric hexavalent combination vaccine dtap mkb mkmk multiple myeloma december ipvhibhepb develop approve grazoprevir cmv prophylaxis transplant patient commercialize partnership merck sanofi pasteur pneumoconjugate vaccine letermovir june november fda issue crl respect contraception generation ring company review crl plan communication mkb september fda diabete mellitus omarigliptin september ertugliflozin november mka ertugliflozinsitagliptin september mkb ertugliflozinmetformin august february mkj sitagliptinipragliflozin october japan ebola vaccine march herpe zoster inactivated vzv vaccine december hiv doravirine december osteoporosis odanacatib september employee december company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group restructure program company initiate action global restructuring program restructuring program global initiative sharpen commercial research development focus action table content program primarily include elimination position sale administrative headquarters organization research development additionally action include reduction company global real estate footprint improvement efficiency manufacturing supply network inception restructuring program december merck eliminate approximately position comprise employee separation elimination contractor vacant position action restructure program substantially complete end merger restructuring program subsequent merck scheringplough merger merger company commence action global restructuring program merger restructuring program design streamline cost structure combine company action program initiate action program primarily include elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility inception merger restructuring program december merck eliminate approximately position comprise employee separation elimination contractor vacant position nonfacility relate restructuring action merger restructuring program substantially complete environmental matter company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million aggregate year amount consider potential recovery party company take active role identify accrue cost management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure material adverse effect company financial position result operation liquidity capital resource year merck believe climate change present risk business potential impact climate change business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy water use greenhouse gas emission company believe risk material business time geographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states percentage total company sale sale sale sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition merck expand operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time financial information geographic area company business provide item financial statement supplementary data table content available information company internet website address wwwmerckcom company available free charge investor portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec companys corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutleadership information available print stockholder request company item risk factor investor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent infringement similar claim company company aggressively defend important patent outside united state include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic pharmaceutical product time time file abbreviate new drug application fda seek market generic form company product prior expiration relevant patent own company company normally respond vigorously defend patent include filing lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation court decision relate company patent potential legislation relate patent regulatory initiative result erosion intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available case certain product loss result material noncash impairment charge company result operation adversely affect lost sale company successfully launch commercially successful replacement product table content chart list patent protection certain company market product candidate review phase candidate set forth item business patent trademark license company product lose market exclusivity company generally experience significant rapid loss sale product company depend patent provide exclusive marketing right product period time loss patent protection company product typically lead significant rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company business cash flow result operation financial position prospect example court rule propose generic form nasonex infringe company patent nasonex generic form nasonex receive marketing approval united states company experience loss nasonex sale addition company lose patent protection cubicin june pursuant agreement generic manufacturer manufacturer launch united states generic version zetia december key company product generate significant company profit cash flow event adversely affect market lead product material negative impact result operation cash flow company ability generate profit operate cash flow depend largely continue profitability company key product januvia zetia janumet gardasilgardasil isentress vytorin result company dependence key product event adversely affect product market product significant impact result operation cash flow event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect result postmarket trial increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale certain product event result material noncash impairment charge company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product year expect decline sale product loss market exclusivity mean company future success dependent pipeline new product include new product develop joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research development process new drug result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result compete product manufacturer reach market clinical trial new drug successful new drug effective harmful effect new drug approve regulator intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing table content company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial position prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection acquisition company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction proposes market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval table content development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval include result postmarkete phase trial study decrease demand company product include follow rereview product market new scientific information evolution scientific theory recall loss marketing approval product market change government standard public expectation safety efficacy labeling change great scrutiny advertising promotion past year clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pharmaceutical medical device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity company face intense competition low costgeneric product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak united states united states political pressure reduce spending prescription drug lead legislation measure encourages use generic product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial position prospect company face intense competition competitor product addition factor certain circumstance lead noncash impairment charge company product face intense competition competitor product competition increase new product enter market event competitor product safer effective table content convenient use effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial position prospect addition product measure fair value capitalize connection acquisition experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product company face pricing pressure respect product company face increase pricing pressure globally particularly mature market manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure company face risk litigation government pricing calculation addition large customer future ask receive high rebate drug certain highly competitive category company compete place formulary manage care organization exclusion product formulary lead reduce usage manage care organization outside united states numerous major market include japan pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product company expect pricing pressure increase future health care industry united states continue subject increase regulation political action company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider congress state legislature united states enact major health care reform legislation patient protection affordable care act insurance market reform advance state federal insurance exchange launch end decade law expect expand access health care million americans previously insurance coverage respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole pharmaceutical manufacturer require pay annual nontax deductible health care reform fee total annual industry fee billion remain billion fee assess company proportion share prior year brand pharmaceutical sale certain government program medicare medicaid january centers medicare medicaid services issue medicaid rebate final rule implement provision patient protection affordable care act effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid programs merck evaluate rule determine material impact merck medicaid rebate liability table content company predict likelihood future change health care industry general pharmaceutical industry particular impact company result operation financial condition business uncertainty global economic condition austerity measure take certain government negatively affect company operating result uncertainty global economic condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial position prospect global effort health care cost containment continue exert pressure product pricing market access international market governmentmandate pricing action reduce price generic patent drug addition austerity measure negatively affect company revenue performance company anticipate pricing action include biennial price reduction japan occur austerity measure continue negatively affect revenue performance credit economic condition worsen result economic currency impact affect market globally material adverse effect company result company significant global operation expose additional risk adverse event material negative impact company result operation extent company operation outside united states significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease past company experience difficulty delay manufacture certain product previously disclose merck past experienced difficulty manufacture certain vaccine product company future experience difficulty delay inherent manufacturing product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture construction delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply manufacturing difficulty result product shortage lead lose sale reputational harm company table content company able realize expect benefit investment emerge market company take step increase sale emerge market guarantee company effort expand sale market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect addition china commercial economic condition adversely affect company growth prospect market company continue believe china represent important growth opportunity event couple heighten scrutiny health care industry continue impact product pricing market access generally company anticipate report inquiry governmental authority involve multinational pharmaceutical company china continue reason sale emerge market carry significant risk failure continue expand company business emerge market material adverse effect business financial condition result company operation company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter acquisition licensing borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate negatively affect company result operation financial position cash flow occur respect venezuela order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful company subject evolve complex tax law result additional liability affect result operation company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return periodically examine tax authority company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue march president obamas administration repropose significant change international tax law include change tax company excess return attributable certain offshore intangible asset limit tax deduction expense relate unrepatriated foreignsource income modify foreign tax credit rule potentially significant change international law include territorial tax system tax currently accumulate unrepatriated foreign earning control foreign corporation set congressional committee company determine proposal enact law change proposal prior enact law change international tax law enact significant impact financial result company table content addition company affect change tax law include tax rate change change law relate remittance foreign earning deferral limitation impact tax treatment foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action reliance party relationship outsource arrangement adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company party service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown invasion corruption destruction interruption critical information technology system infrastructure company workforce authorize access company system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction confidential information store company system nonencrypte portable medium storage device company experience business interruption intentional theft confidential information reputational damage espionage attack malware cyberattack insider threat attack compromise company system infrastructure lead datum leakage internally company thirdparty provider aggregate impact company operation financial condition material date company target event nature expect continue company monitor datum information technology personnel usage company system reduce risk continue ongoing basis current potential threat assurance company effort protect datum system prevent service interruption loss critical sensitive information company company party provider database system result financial legal business reputational harm company negative event animal health industry negative impact future result operation future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal bovine spongiform encephalopathy mad cow disease lead widespread death precautionary destruction reduce consumption demand animal adversely impact company result operation outbreak highly contagious disease near company main production site require company immediately halt production vaccine site force company incur substantial expense procure raw material vaccine risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event animal health segment company business significant impact event future result operation significant table content biologic carry unique risk uncertainty negative impact future result operation successful development testing manufacturing commercialization biologic particularly human animal health vaccine long expensive uncertain process unique risk uncertaintie biologic include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction united states result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example united states bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval require release manufacture commercial lot manufacture biologic especially large quantity complex require use innovative technology handle living micro organism lot approve biologic undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company require provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic frequently costly manufacture production ingredient derive live animal plant material biologic synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead allegation harm include infection allergic reaction closure product facility possible contamination event result substantial cost product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost increase significantly respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability legacy merck product sell date company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise change law regulation adversely affect company business aspect company business include research development manufacturing marketing pricing sale litigation intellectual property right subject extensive legislation regulation change applicable federal state law agency regulation material adverse effect company business table content social medium platform present risk challenge inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment company social networking web site damage company reputation brand image goodwill disclosure nonpublic company sensitive information company workforce external medium channel lead information loss internal company social medium policy guide employee appropriate personal professional use social medium company process place completely secure protect information identify new point entry social medium continue expand present new challenge cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forward look statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant change customer relationship change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product table content lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state united states require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment item property companys corporate headquarter locate kenilworth new jersey company commercial operation headquarter upper gwynedd pennsylvania company pharmaceutical business conduct divisional headquarters locate upper gwynedd cokesbury new jersey company vaccine business conduct divisional headquarters locate west point pennsylvania mercks animal health global headquarters function locate madison new jersey principal research facility locate rahway kenilworth new jersey west point pennsylvania palo alto california boston massachusetts elkhorn nebraska animal health principal research facility outside united states locate switzerland china mercks manufacturing operation headquarter whitehouse station new jersey company production facility human health product location united states puerto rico outside united states subsidiary company own interest manufacturing plant property japan singapore south africa countries western europe central south america asia capital expenditure billion billion billion united states amount million million million abroad expenditure amount million million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference item financial statement supplementary datum note contingency environmental liability item safety disclosure applicable table content executive officer registrant age february kenneth frazi age december chairman president chief executive officer january president chief executive officer president responsible company large global division global human health merck manufacturing division merck research laboratory prior frazi executive vice president president global human health adele ambrose age november senior vice president chief communication officer responsible global communication organization robert davis age april executive vice president chief financial officer responsible company global financial organization investor relation corporate strategy business development global facility company joint venture relationship prior april davis corporate vice president president medical products baxter international inc baxter corporate vice president president renal division baxter baxter corporate vice president chief financial officer willie deese age november executive vice president president merck manufacturing division responsible company global manufacturing procurement distribution logistic function richard deluca age september executive vice president president merck animal health responsible merck animal health organization prior september deluca chief financial officer becton dickinson bioscience medical technology company president wyeths fort dodge animal health division julie gerberde mph age january executive vice president strategic communication global public policy population health responsible merck global public policy corporate responsibility global communication function january president merck vaccines responsible merck portfolio vaccine plan introduction vaccine company pipeline accelerate effort broaden access merck vaccine world table content clark golestani age december executive vice president chief information officer responsible company global information technology organization august vice president merck research laboratorie information technology responsible global company research development division include basic research preclinical clinical regulatory mirian graddickweir age november executive vice president human resource responsible global human resource organization michael holston age july executive vice president general counsel responsible company legal function june executive vice president chief ethic compliance officer responsible company global compliance function include global safety environment system assurance ethic privacy security organization prior june holston executive vice president general counsel board secretary hewlettpackard company oversaw legal compliance government affair privacy ethic operation rita karachun age march senior vice president finance global controller responsible company global controller organization include accounting control external reporting financial standard policy november assistant controller responsible global consolidation company entity act controller base entities roger perlmutter phd age april executive vice president president merck research laboratory responsible company global research development effort prior april perlmutter executive vice president research development amgen inc michael rosenblatt age december executive vice president chief medical officer company primary voice global medical community critical issue patient safety benefitrisk medication adam schechter age executive vice president president global human health responsible company global pharmaceutical vaccine business november president global human health market integration leader commercial responsibility united states company portfolio prescription medicine leader integration effort merckscheringplough merger division function officer list serve pleasure board director officer elect pursuant arrangement understand officer board table content item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk common stock market price information set forth table base historical nyse market price follow table set forth calendar period indicate dividend share information cash dividend pay common share year common stock market price high low high low january approximately shareholder record issuer purchase equity security month end december follow issuer purchase equity security millions total number average price approximate dollar value share share pay purchase period purchase share plan programs october october november november december december total share purchase period plan approve board director march purchase billion merck share table content performance graph follow graph assume investment december reinvestment dividend companys common share index composite peer group major usbased pharmaceutical company abbvie inc bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck inc composite peer group index end period value cagr merck peer grp merck peer grp compound annual growth rate peer group average calculate market cap weight basis addition abbvie inc replace abbott laboratories peer group begin follow spin abbott laboratories performance graph deem incorporate reference file security act securities exchange act extent company specifically incorporate reference addition performance graph deem soliciting material file sec subject regulation provide regulation liabilities section securities exchange act extent company specifically request information treat soliciting material specifically incorporate reference filing security act exchange act table content item select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report merck inc subsidiarie million share amount result year sale material production marketing administrative research development restructuring cost income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder cash dividend declare cash dividend declare common share capital expenditure depreciation average common share outstanding million average common share outstanding assume dilution million yearend position work capital property plant equipment net total asset longterm debt total equity yearend statistic number stockholder record number employee amount include net charge relate settlement vioxx shareholder class action litigation foreign exchange loss relate venezuela gain disposition business asset favorable benefit certain tax item amount reflect divestiture merck consumer care business october include gain sale gain recognize option exercise astrazeneca gain disposition business asset loss extinguishment debt amount include net charge record connection settlement certain shareholder litigation amount include arbitration settlement charge amount restate effect early adoption accounting guidance issue financial accounting standard board note item financial statement table content item management discussion analysis financial condition result operation description merck business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health alliance healthcare service segment pharmaceutical segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer merck alliance segment primarily include result company relationship astrazeneca termination relationship june companys healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient october company divest consumer care segment develop manufacture market overthecounter foot care sun care product overview merck continue execute research development focusedstrategy advance pipeline commercial portfolio maintain discipline approach cost management deliver capital return shareholder company receive product approval include expand indication keytruda company antipd program death receptor therapy treatment advanced melanoma metastatic non smallcell lung cancer nsclc patient tumor express pdl disease progression follow therapy food drug administration fda approval bridion sugammadex injection medication reversal type neuromuscular block agent surgery additionally january fda approve zepatier oncedaily single tablet combination therapy treatment chronic hepatitis virus hcv genotype infection ribavirin business development critical company strategy merck look combine internal external innovation enhance pipeline merck acquire cubist pharmaceutical inc cubist leader development new therapy treat potentially lifethreatening infection cause broad range increasingly drugresistant bacteria ccam biotherapuetics ltd ccam biopharmaceutical company focus discovery development novel cancer immunotherapy merck enter multiyear collaboration ngm biopharmaceutical inc ngm research discover develop commercialize novel biologic therapy wide range therapeutic area january merck acquire iomet pharma ltd iomet drug discovery company focus development innovative medicine treatment cancer particular emphasis field cancer immunotherapy cancer metabolism worldwide sale billion decline compare include unfavorable effect foreign exchange acquisition cubist divestiture merck consumer care business mcc product divestiture termination company relationship astrazeneca azlp net unfavorable impact sale approximately sale performance unfavorably affect ongoing impact loss market exclusivity product unfavorable impact partially offset volume growth oncology diabete women health vaccine product positive performance merck animal health business merck continue support inline portfolio ongoing upcoming product launch keytruda initially approve fda september treatment advanced melanoma patient disease progression therapy launch market include european union merck achieve multiple additional regulatory milestone keytruda include accelerate approval fda table content treatment patient metastatic nsclc tumor express pdl determine fdaapprove test disease progression platinumcontaine chemotherapy addition fda approve expand indication keytruda include firstline treatment patient unresectable metastatic melanoma additionally european commission approve keytruda treatment advance unresectable metastatic melanoma adult keytruda clinical trial program currently include tumor type clinical trial include trial combine keytruda cancer treatment research development company launch zepati bridion united states company continue execute strategy pursue business development opportunity complement internal research capability merck prioritization effort company continue review exist asset determine provide good short longerterm value merck connection portfolio assessment process company divest remain ophthalmic business international market company portfolio assessment process ongoing future divestiture occur merck focus research effort therapeutic area believe impact address critical area unmet medical need cancer hepatitis cardiometabolic disease resistant microbial infection alzheimer disease company continue stride latestage pipeline bezlotoxumab investigational antitoxin prevention clostridium difficile difficile infection recurrence currently review fda european medicines agency ema insulin glargine candidate treatment patient type type diabete develop collaboration review zepatier keytruda review treatment nsclc addition phase program keytruda therapeutic area bladder breast colorectal gastric head neck multiple myeloma esophageal cancer company candidate phase clinical development core therapeutic area area significant potential include omarigliptin investigational onceweekly dipeptidyl peptidase dpp inhibitor development treatment adult type diabete odanacatib oral onceweekly investigational treatment patient osteoporosis ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate combination januvia sitagliptin metformin treatment type diabete investigational allergy immunotherapy tablet house dust mite allergy merck expect submit application regulatory approval united states candidate describe result continued portfolio prioritization company outlicense discontinuing select latestage clinical development asset company outlicense investigational small molecule oral calcitonin generelate peptide cgrp receptor antagonist develop treatment prevention migraine company continue strong progress reduce cost base result discipline cost management merck achieve overall saving goal note company turn invest resource grow strong brand support promise asset pipeline marketing administrative expense decline compare reflect continue focus company prioritize resource high growth area company initiate action global restructuring program restructuring program global initiative sharpen commercial research development focus action program primarily include elimination position sale administrative headquarters organization research development additionally action include reduction company global real estate footprint improvement efficiency manufacture supply network company record total pretax cost million billion related restructuring program action restructure program substantially complete end company meet project billion annual net cost saving action restructure program action restructure program combine action merger restructuring program discuss company meet annual net cost saving projection billion compare fullyear expense level table content global restructuring program merger restructuring program initiate subsequent merck scheringplough corporation scheringplough merger merger intend streamline cost structure combine company action plan include elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company record total pretax cost million million billion related restructuring program nonfacility relate restructuring action merger restructuring program substantially complete beginning january remain restructuring action plans primarily relate ongoing facility rationalization account aggregate prospectively company expect complete action end incur approximately billion additional pretax cost cost associate company restructure action include material production cost market administrative expense research development expense restructure cost company estimate approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest november mercks board director raise company quarterly dividend share share company return billion shareholder dividend share repurchase january merck announce reach agreement plaintiff resolve vioxx shareholder class action litigation pende new jersey federal court agreement merck pay million resolve settlement class member claim plus additional approve attorney fee expense connection settlement merck record net pretax charge million fourth quarter include anticipate insurance recovery note consolidated financial statement earning common share assume dilution attributable common shareholder ep compare eps year reflect impact acquisition divestiturerelate cost restructure cost certain item include billion gain recognize connection divestiture mcc nongaap eps exclude item nongaap income nongaap eps competition health care environment competition market company conduct business pharmaceutical industry general highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug manufacturer animal health care company companys operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent right increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect intangible asset associate certain product competitive pressure intensify pressure industry grow pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance license arrangement refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number table content compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient backdrop united states enact major health care reform legislation patient protection affordable care act began implement insurance market reform advance state federal insurance exchange launch end decade law expect expand access health care million americans previously insurance coverage respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million million record merck reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual nontax deductible health care reform fee total annual industry fee billion remain billion fee assess company proportion share prior year brand pharmaceutical sale certain government program medicare medicaid company record million million million cost marketing administrative expense respectively annual health care reform fee high expense reflect final regulation annual health care reform fee issue internal revenue service irs july final irs regulation accelerate recognition criterion fee obligation year year underlie sale allocate fee occur year fee pay result change merck record additional year expense million january center medicare medicaid services issue medicaid rebate final rule implement provision patient protection affordable care act effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid programs merck evaluate rule determine material impact merck medicaid rebate liability company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care organization federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure example health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue generating cost saving proposal include additional direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company table content effort health care cost containment remain intense european country country continue announce execute austerity measure include implementation pricing action reduce price generic patent drug mandatory switch generic drug company take step mitigate impact country austerity measure continue negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance addition majority country attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug brand authority use price data market set new local price brandname drug include company guideline examine reference pricing usually set local market change pursuant local regulation addition japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine occur furthermore government order repricing class drug determine appropriate applicable rule certain market outside united states implement cost management strategy health technology assessment require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement company focus emerge market increase government emerge market focus constrain health care cost enact price control relate measure compulsory license aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states time fda commit expedite development review product bear breakthrough therapy designation appears accelerate regulatory review process medicine designation table content adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment operating result sale worldwide sale billion decline compare include unfavorable effect foreign exchange acquisition cubist divestiture mcc product divestiture termination company relationship astrazeneca azlp discuss net unfavorable impact sale approximately addition sale performance reflect decline pegintron victrelis medicine treatment hcv remicade treatment inflammatory disease pneumovax vaccine help prevent pneumococcal disease nasonex inhale corticosteroid treatment nasal allergy symptom vytorin cholesterol modify medicine decline partially offset volume growth keytruda antipd therapy januvia janumet treatment type diabete gardasilgardasil vaccine help prevent certain disease cause certain type human papillomavirus hpv noxafil prevention invasive fungal infection simponi oncemonthly subcutaneous treatment inflammatory disease implanonnexplanon singlerod subdermal contraceptive implant invanz treatment certain infection dulera inhalation aerosol combination medicine treatment asthma bridion medication reversal type neuromuscular block agent surgery volume growth animal health product high thirdparty manufacturing sale january company acquire cubist contribute sale billion merck revenue company divest certain ophthalmic product international market close july addition october company divest mcc business include prescription right claritin afrin sale decline attributable divestiture approximately billion billion related consumer care segment million relate pharmaceutical segment company sell marketing right saphris antipsychotic indicate treatment schizophrenia bipolar disorder adult result revenue million additionally company relationship azlp terminate june effective july company long record supply sale azlp supply sale million termination date reflect alliance segment sales united states billion increase compare billion increase drive primarily acquisition cubist high sale keytruda gardasilgardasil januviajanumet zetia cholesterol modify medicine high thirdparty manufacturing sale increase partially offset divestiture mcc termination company relationship azlp revenue recognize connection sale marketing right saphris low sale pneumovax nasonex international sale billion decline compare billion foreign exchange unfavorably affect international sale performance exclude unfavorable effect foreign exchange sale decrease reflect divestiture mcc low sale pharmaceutical segment largely reflect decline europe japan partially offset growth emerge market sale europe decline billion include unfavorable effect foreign exchange exclude unfavorable effect foreign exchange decline drive primarily low sale remicade low sale product treatment hcv product divestiture ongoing generic erosion fiscal austerity measure region partially offset growth simponi keytruda januviajanumet sale japan decline billion unfavorable effect foreign exchange sale decline largely drive product divestiture ongoing impact loss market exclusivity product include cozaar hyzaar treatment hypertension low sale pegintron januvia table content sale emerge market billion decline include unfavorable effect foreign exchange exclude unfavorable effect foreign exchange sale performance reflect volume growth diabete hospital acute care oncology certain diversified brand product partially offset low sale hcv product product divestiture total international sale represent total sale respectively global effort health care cost containment continue exert pressure product pricing market access worldwide united states health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate international market governmentmandate pricing action reduce price generic patent drug addition austerity measure negatively affect company revenue performance company anticipate pricing action include biennial price reduction japan occur austerity measure continue negatively affect revenue performance worldwide sale total billion decline compare billion foreign exchange unfavorably affect global sale performance decline reflect low revenue result ongoing impact loss market exclusivity product include temodar treatment certain type brain tumor singulair onceaday oral medicine chronic treatment asthma relief symptom allergic rhinitis cozaar hyzaar addition sale decline attributable product divestiture occurred discuss termination company relationship azlp divestiture mcc revenue decline drive low sale victrelis pegintron nasonex vytorin decline partially offset growth remicade simponi diabete franchise januviajanumet dulera inhalation aerosol implanonnexplanon high sale hospital acute care animal health product addition company recognize revenue million connection sale marketing rights saphris october company sell active pharmaceutical ingredient api manufacturing business effective december certain relate product diversified brand november merck sell right certain ophthalmic product january sell marketing right saphris addition company sell right zioptan april note company divest certain ophthalmic product international market sell mcc business sale decline attributable divestiture approximately billion approximately million related pharmaceutical segment million relate consumer care segment million relate divested api manufacturing business nonsegment revenue termination company relationship azlp result sale decline approximately million alliance segment compare table content sale company product follow million primary care women health cardiovascular zetia vytorin diabete januvia janumet general medicine women health nuvare implanonnexplanon dulera follistim hospital specialty hepatitis pegintron hiv isentress hospital acute care cubicin cancidas invanz noxafil bridion primaxin immunology remicade simponi oncology keytruda emend temodar diversify brand respiratory singulair nasonex clarinex cozaarhyzaar arcoxia fosamax zocor propecia vaccine gardasilgardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sale segment sale total segment sale sale cubicin represent sale subsequent cubist acquisition date sale cubicin reflect sale japan pursuant previously exist licensing agreement amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate include income expense net amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment animal health alliance healthcare service consumer care divestiture october alliance segment include revenue company relationship azlp termination june revenues primarily comprise miscellaneous corporate revenue include revenue hedging activity thirdparty manufacture sale revenue include million receive merck connection sale marketing right saphris revenue reflect million revenue outlicense pipeline compound table content pharmaceutical segment primary care women health cardiovascular combine global sale zetia market country outside united states ezetrol vytorin market outside united states inegy medicine lower ldl cholesterol billion decline compare include unfavorable effect foreign exchange sale decline drive primarily low volume ezetrol canada lose market exclusivity september low volume united states partially offset high pricing united states combine worldwide sale zetia vytorin billion decline compare foreign exchange unfavorably affect global sale performance sale decline drive primarily low volume vytorin united states ezetrol canada loss market exclusivity november merck announce investigational improveit study improve reduction outcome vytorin efficacy international trial meet primary secondary composite efficacy endpoint improveit patient take vytorin combine simvastatin zetia experience significantly few major cardiovascular event measure composite cardiovascular death nonfatal myocardial infarction nonfatal stroke hospitalization unstable angina coronary revascularization occur day randomization patient treat simvastatin result patient study highrisk patient present acute coronary syndrome present american heart association scientific session april merck submit datum improveit fda support new indication reduction cardiovascular event vytorin zetia vytorin zetia currently indicate use healthy diet reduce elevated ldl cholesterol patient hyperlipidemia current prescribe information product states effect ezetimibe cardiovascular morbidity mortality incremental statin therapy determine february merck announce fda issue complete response letter crl merck supplemental new drug application merck reviewing letter determine step february decentralize process merck receive positive outcome mutual recognition procedure update product information ezetrol inegy base result improveit follow completion procedure member states concerned amend local labeling country country basis include reduction risk cardiovascular event patient coronary heart disease history acute coronary syndrome agreement generic manufacturer launch generic version zetia united states december patent exclusivity period zetia vytorin expire april company market exclusivity ezetrol major european market october company expect apply pediatric extension term extend date april company market exclusivity inegy market april merck announce fda approve zontivity reduction thrombotic cardiovascular event patient history myocardial infarction peripheral arterial disease prescribe information zontivity include box warning bleed risk january zontivity approve coadministration acetylsalicylic acid appropriate clopidogrel reduce atherothrombotic event adult patient history myocardial infarction merck currently plan begin launch zontivity certain european market company continue monitor assess zontivity relate intangible asset merck continue focus build product awareness united states zontivity company effort build product awareness united states launch europe successful company noncash impairment charge respect zontivity intangible asset million december diabete worldwide combine sale januvia janumet medicine help lower blood sugar level adult type diabete billion essentially flat compare include unfavorable effect foreign exchange sale performance reflect high volume pricing united states volume growth emerge market europe volume decline comarkete sitagliptin japan time sale licensee partially offset growth combine global sale januvia janumet billion increase compare include unfavorable effect foreign exchange table content growth drive primarily high sale januvia janumet united states volume growth europe partially offset low sale januvia japan low pricing april dpp inhibitor include januvia subject reprice japan june merck announce primary result trial evaluate cardiovascular outcome sitagliptin tecos placebocontrolle study cardiovascular safety mercks dpp inhibitor januvia sitagliptin add usual care patient study achieve primary composite endpoint noninferiority define time confirm event follow cvrelate death nonfatal myocardial infarction nonfatal stroke hospitalization unstable angina compare usual care sitagliptin addition increase hospitalization heart failure rate allcause mortality similar treatment group key secondary endpoint datum present annual scientific meeting american diabetes association june september merck announce japanese pharmaceutical medical device agency approve marizev omarigliptin tablet oral onceweekly dpp inhibitor indicate treatment adult type diabete japan country approve omarigliptin worldwide regulatory submission follow general medicine women health worldwide sale nuvare vaginal contraceptive product million increase compare million increase compare foreign exchange unfavorably affect global sale performance respectively sale growth year largely reflect high pricing united states worldwide sale implanonnexplanon singlerod subdermal contraceptive implant rise million increase compare include unfavorable effect foreign exchange increase drive primarily high demand united states emerge market implanonnexplanon sale grow million compare drive primarily high demand united states global sale dulera inhalation aerosol combination medicine treatment asthma grow million increase million drive primarily high demand united states global sale follistim market country outside united states puregon fertility treatment million decline compare reflect unfavorable effect foreign exchange offset high pricing united states worldwide sale follistim decline million compare drive largely low pricing united states low sale europe drive primarily volume decline foreign exchange unfavorably affect global sale performance patent provide market exclusivity follistim united states expire june hospital specialty hepatitis worldwide sale pegintron treatment chronic hcv million decline compare include unfavorable effect foreign exchange decline drive low volume nearly region availability new therapeutic option continue reduce market share global sale pegintron million decline compare include unfavorable effect foreign exchange decrease drive low volume region availability new therapeutic option result loss market share lead patient treatment delay market anticipate availability new therapeutic option global sale victrelis oral medicine treatment chronic hcv million decline compare drive low volume europe emerge market availability new therapeutic option continue reduce market share worldwide sale victrelis million decline compare drive low volume nearly region particularly united states availability new therapeutic option result loss market share lead patient treatment delay market anticipate availability new therapeutic option table content january fda approve zepati treatment adult patient chronic hcv infection ribavirin zepatier oncedaily fixeddose combination tablet contain nsa inhibitor elbasvir nsa protease inhibitor grazoprevir fda previously grant breakthrough therapy designation zepati treatment chronic hcv infection patient end stage renal disease hemodialysis treatment patient chronic hcv infection breakthrough therapy designation give investigational medicine lifethreatening condition offer substantial improvement exist therapy multiple clinical study zepatier achieve high rate sustain virologic response range gtinfecte patient gtinfecte patient sustain virologic response define hcv rna level measure low limit quantification week cessation treatment indicate patient hcv infection cure zepatier available united states february zepatier review hiv worldwide sale isentress hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection billion decline compare include unfavorable effect foreign exchange decline drive primarily low volume united states low demand pricing europe competitive pressure partially offset high volume latin america high pricing united states global sale isentress increase billion compare primarily reflect volume growth europe emerge market particularly latin america result government tender partially offset volume decline united states reflect competitive pressure foreign exchange unfavorably affect global sale performance hospital acute care january merck acquire cubist leader development therapy treat infection cause broad range bacteria cubist product include cubicin antibiotic complicated skin skin structure infection bacteremia cause designate susceptible organism sale cubicin billion subsequent acquisition composition patent cubicin expire june significant loss cubicin sale expect occur market outside united states cubicin commercialize company accordance distribution agreement establish prior merck acquisition cubist fourth quarter merck enter agreement reacquire marketing right cubicin certain international market include europe latin america australia new zealand china south africa certain asia pacific country cubist product include zerbaxa combination product approve fda december treatment adult complicated urinary tract infection cause designate susceptible gramnegative organism complicate intraabdominal infection cause designate susceptible gramnegative grampositive organism sivextro product approve fda june treatment acute bacterial skin skin structure infection absssi adult cause designate susceptible grampositive organism sivextro approve march treatment absssi adult company begin launch sivextro second quarter september zerbaxa approve treatment complicate intraabdominal infection acute pyelonephritis complicated urinary tract infection adult zerbaxa sivextro phase development united states treatment hospitalacquire bacterial pneumonia ventilatorassociate bacterial pneumonia global sales cancidas antifungal product million decrease compare reflect unfavorable effect foreign exchange volume decline certain emerge market worldwide sale cancida grow million compare largely reflect volume growth asia pacific region particularly china foreign exchange unfavorably affect global sale performance worldwide sale noxafil prevention invasive fungal infection grow million increase million drive pricing high demand united states volume growth europe reflect positive impact approval new formulation foreign exchange unfavorably affect global sale performance table content sale bridion reversal type neuromuscular block agent surgery grow million rise million drive volume growth international market sell foreign exchange unfavorably affect global sale performance bridion approve market country outside united states december fda approve bridion reversal neuromuscular blockade induce rocuronium bromide vecuronium bromide adult undergo surgery immunology sale remicade treatment inflammatory disease market company europe russia turkey billion decline compare include unfavorable effect foreign exchange february company lose market exclusivity remicade major european market long market exclusivity marketing territory company experience pricing volume decline market result biosimilar competition company retain majority exist patient company lose market share new patient prescribe biosimilar company expect remicade sale decline accelerate sale remicade billion increase compare reflect sale growth europe partially offset decline russia sale simponi oncemonthly subcutaneous treatment certain inflammatory disease market company europe russia turkey million essentially flat compare drive high demand europe reflect ongoing positive impact ulcerative colitis indication offset unfavorable effect foreign exchange sale simponi grow million compare drive demand europe reflect positive impact ulcerative colitis indication product contain hospital specialty include invanz treatment certain infection primaxin antibacterial product oncology sale keytruda antipd program death receptor therapy million million increase primarily reflect high sale united states emerge market europe company continue launch keytruda september fda grant accelerated approval keytruda dose mgkg week treatment patient unresectable metastatic melanoma disease progression follow ipilimumab braf mutation positive braf inhibitor december company announce fda approve expand indication keytruda include firstline treatment patient unresectable metastatic melanoma regardless braf status additionally fda approve update product label keytruda treatment patient ipilimumabrefractory advanced melanoma addition october fda grant accelerated approval keytruda dose mgkg week treatment patient metastatic nsclc tumor express pdl determine fdaapprove test disease progression platinumcontaine chemotherapy squamous nonsquamous metastatic nsclc patient egfr alk genomic tumor aberration disease progression fdaapprove therapy aberration prior receive keytruda addition approve keytruda nsclc fda approve companion diagnostic enable physician determine level pdl expression patient tumor july merck announce approve keytruda treatment advance unresectable metastatic melanoma adult october merck announce national institute health care excellence nice issue draft recommendation form final appraisal determination recommend keytruda firstline treatment option adult advanced melanoma addition nice issue final guidance recommend keytruda treatment advanced melanoma disease progression ipilimumab company additional regulatory filing country filing plan keytruda clinical development program include study broad range cancer type research development table content global sale emend prevention chemotherapyinduce postoperative nausea vomit million decline reflect unfavorable effect foreign exchange partially offset high pricing united states volume growth europe worldwide sale emend million increase compare include unfavorable effect foreign exchange largely reflect volume growth region february merck announce fda approve supplemental new drug application singledose emend injection prevention delay nausea vomit adult receive initial repeat course moderately emetogenic chemotherapy approval emend injection intravenous singledose receptor antagonist approve united states highly emetogenic chemotherapy moderately emetogenic chemotherapy sale temodar market temodal outside united states treatment certain type brain tumor million decline compare reflect unfavorable effect foreign exchange partially offset growth emerge market global sale temodar decline million foreign exchange unfavorably affect global sale performance sale decline drive primarily generic competition united states europe agreement generic manufacturer launch generic version temodar united states august patent exclusivity period expire february diversify brand mercks diversify brand include human health pharmaceutical product approach expiration marketing exclusivity long protect patent develop market continue core company offer market world respiratory worldwide sale singulair onceaday oral medicine chronic treatment asthma relief symptom allergic rhinitis million decline compare include unfavorable effect foreign exchange sale decline drive primarily low volume japan low demand europe result generic competition global sale singulair billion decline compare include unfavorable effect foreign exchange primarily reflect low sale europe result generic competition company lose market exclusivity singulair united states major international market exception japan expect generic competition market continue patent provide market exclusivity singulair japan expire singulair sale japan million global sale nasonex inhale nasal corticosteroid treatment nasal allergy symptom million decline compare include unfavorable effect foreign exchange decline drive primarily low volume united states reflect competition alternative generic treatment option supply constraint supply issue resolve nasonex available october addition low volume price europe ongoing generic erosion contribute nasonex sale decline agreement generic manufacturer able launch generic version nasonex european market january generic version nasonex launch market accordingly company continue experience volume pricing decline nasonex sales europe worldwide sales nasonex decrease billion compare foreign exchange unfavorably affect global sale performance sale decline drive primarily low demand united states low volume europe canada result generic competition apotex inc apotex corp collectively apotex file application fda seek approval sell generic version nasonex june district court district new jersey rule company patent infringement suit apotex hold apotexs generic version nasonex infringe company formulation patent june court appeal federal circuit issue decision affirm district court decision company exhaust appeal option apotex launch generic version nasonex united states apotexs generic version available significant loss nasonex sale occur sale nasonex million table content global sale cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension decline million decrease million foreign exchange unfavorably affect global sale performance respectively patent provide market exclusivity cozaar hyzaar united states major international market expire accordingly company experience decline cozaar hyzaar sale expect decline continue worldwide sale ophthalmic product cosopt trusopt million million million decline drive largely divestiture cosopt trusopt international market addition sale right cosopt cosopt contribute sale decline compare december company divest remain ophthalmic portfolio international market mundipharma ophthalmology product limit note consolidated financial statement product contain diversified brand include clarinex nonsedate antihistamine arcoxia treatment arthritis pain company market outside united states fosamax market fosamac japan fosamax plus market fosavance treatment case fosamax prevention osteoporosis zocor statin modifying cholesterol propecia product treatment male pattern hair loss vaccine follow discussion vaccine include sale vaccine sell major european market sanofi pasteur msd spmsd company joint venture sanofi pasteur result reflect equity income affiliate include income expense net select joint venture affiliate information supply sale spmsd include merck sale gardasilgardasil vaccine help prevent certain disease cause certain type hpv billion increase compare include unfavorable effect foreign exchange sale growth drive primarily high sale united states result high pricing increase volume reflect time public sector purchase increase government tender asia pacific region partially offset decline latin america price volume gardasil merck valent hpv vaccine approve fda december use girl young woman year age gardasil include great number hpv type available hpv vaccine december fda approve expand age indication gardasil include use male year age prevention anal cancer precancerous dysplastic lesion genital wart cause certain hpv type merck sale gardasil billion decline compare include unfavorable effect foreign exchange decline reflect low sale asia pacific japan canada partially offset high government tender brazil national immunization program high public sector purchase united states sale include million million respectively purchase center disease control prevention cdc pediatric vaccine stockpile company party certain party license agreement respect gardasilgardasil include crosslicense settlement agreement glaxosmithkline result agreement company pay royalty worldwide gardasilgardasil sale vary country include material production cost merck sale proquad pediatric combination vaccine help protect measle mump rubella varicella million million million sale growth compare drive high sale united states reflect increase volume drive measle outbreak united states high pricing increase compare drive primarily high sale united states reflect approximately million government purchase cdc pediatric vaccine stockpile merck sale mmr vaccine help protect measle mump rubella million million million sale growth compare drive high demand result measle outbreak united states high pricing table content merck sale varivax vaccine help prevent chickenpox varicella million million million sale growth compare reflect high volume certain emerge market high pricing united states partially offset low volume united states sale performance compare reflect low sale united states largely offset growth emerge market merck sale zostavax vaccine help prevent shingles herpe zoster adult year age old million decline compare include unfavorable effect foreign exchange sale performance compare reflect low volume united states partially offset high demand canada high pricing united states merck sale zostavax million increase compare drive primarily high sale asia pacific region ongoing launch partially offset low demand united states canada company continue educate customer broad manage care coverage zostavax process obtain reimbursement merck continue launch zostavax outside united states mercks sale rotateq vaccine help protect rotavirus gastroenteritis infant child million decline compare include unfavorable effect foreign exchange decline drive primarily effect public sector purchasing united states mercks sale rotateq increase million compare primarily reflect high sale certain emerge market merck sale pneumovax vaccine help prevent pneumococcal disease decline million compare drive primarily low demand united states near term market dynamic sale emerge market merck sale pneumovax grow million compare drive primarily high sale japan national immunization program high sale united states attributable price volume foreign exchange unfavorably affect sale performance respectively segment companys segment animal health alliance healthcare service segment material separate report prior disposition october company consumer care segment sale billion billion animal health animal health include pharmaceutical vaccine product prevention treatment control disease major farm companion animal species animal health sale affect competition frequent introduction generic product global sale animal health product billion decline compare include unfavorable effect foreign exchange sale performance reflect volume growth companion animal product drive primarily high sale bravecto chewable tablet dog treat flea tick begin launch europe united states volume growth swine aqua product worldwide sale animal health product total billion growth compare include unfavorable effect foreign exchange sale growth drive primarily high sale companion animal product reflect launch bravecto europe united states high sale poultry aqua product partially offset low sale zilmax feed supplement beef cattle alliance alliance segment include result company relationship azlp june astrazeneca exercise option buy merck interest subsidiary merck interest nexium prilosec result july company long record equity income azlp supply sale azlp primarily relate sale nexium prilosec terminate select joint venture affiliate information revenue azlp million june termination date million table content cost expense million change change material production marketing administrative research development restructuring cost income expense net great include million million million iprd impairment charge respectively material production material production cost billion billion billion cost include expense amortization intangible asset record connection business acquisition total billion billion billion addition expense include million amortization purchase accounting adjustment cubist inventory cost include intangible asset impairment charge million billion million respectively relate market product intangible note consolidated financial statement company recognize additional noncash impairment charge future relate intangible measure fair value capitalize connection acquisition charge material additionally cost include million intangible asset impairment charge relate licensing agreement include material production cost associate restructuring activity amount million million million respectively include accelerate depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare amortization intangible asset purchase accounting adjustment inventory restructuring impairment charge note reduce gross margin percentage point percentage point percentage point exclude impact gross margin improvement compare drive primarily favorable effect foreign exchange low inventory writeoff net impact acquisition divestiture gross margin decline compare drive primarily unfavorable effect inventory writeoff largely relate victreli change product mix partially offset sale marketing right saphris market administrative marketing administrative expense decline billion largely reflect favorable effect foreign exchange prior year divestiture mcc additional expense prior year relate health care reform fee discuss low restructuring cost low selling cost partially offset high promotional spending largely relate product launch high cost relate january acquisition cubist high acquisition divestiturerelated cost market administrative expense decrease billion drive primarily low selling cost promotional spending divestiture mcc favorable effect foreign exchange partially offset additional year expense relate health care reform fee high acquisition divestiturerelated cost expense include restructure cost million million million respectively relate primarily accelerate depreciation facility close divest separation cost associate sale force reduction incur reflect restructure cost discuss expense include million million million acquisition divestiturerelated cost respectively consist integration transaction certain cost relate business acquisition include severance cost company formal restructuring program transaction certain cost relate divestiture table content july irs issue final regulation annual nontax deductible health care reform fee impose patient protection affordable care act base allocation company market share prior year brand pharmaceutical sale certain government program final irs regulation accelerate recognition criterion fee obligation year year underlie sale allocate fee occur year fee pay result change merck record additional year expense million research development research development expense billion decline compare billion drive primarily favorable effect foreign exchange expense recognize prior year increase estimate fair value liability contingent consideration low restructuring cost charge prior year relate collaboration bayer bayer prior year divestiture mcc partially offset acquisition cubist high licensing cost high clinical development spending research development expense decline billion compare billion reflect target reduction low clinical development spend result portfolio prioritization cost saving result restructure activity lower acquire inprocess research development iprd impairment charge partially offset high charge increase estimate fair value liability contingent consideration high restructuring cost charge relate collaboration bayer research development expense comprise cost directly incur merck research laboratory mrl company research development division focus human healthrelated activity approximately billion billion billion include research development expense cost incur division support research development activity include depreciation production general administrative licensing activity certain cost operate segment include pharmaceutical animal health segment aggregate billion billion billion respectively research development expense include iprd impairment charge million million million respectively research development company recognize additional noncash impairment charge future cancellation delay pipeline program measure fair value capitalize connection acquisition charge material addition research development expense include expense income relate change estimate fair value measurement liability contingent consideration record connection acquisition company record reduction expense million decrease fair value liability contingent consideration record charge million increase estimate fair value liability contingent consideration note consolidated financial statement research development expense reflect million million million respectively accelerate depreciation asset abandonment cost associate restructuring activity restructure cost restructure cost primarily represent separation relate cost associate restructuring activity million billion billion respectively cost include million million million respectively expense related restructuring program remain cost nearly remain cost record related merger restructuring program separation cost million million billion respectively incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate position eliminate restructure program approximately position eliminate merger restructuring program approximately position elimination comprise actual headcount reduction elimination contractor vacant position include restructuring cost asset abandonment shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include material production marketing administrative research development discuss table content income expense net income expense net billion expense compare billion income unfavorability drive primarily gain recognize include billion gain relate divestiture mcc note consolidated financial statement million gain relate astrazenecas option exercise note consolidated financial statement million gain divestiture certain ophthalmic product international market note consolidated financial statement million gain relate divestiture company sirna therapeutics inc subsidiary note consolidated financial statement unfavorability drive million net charge record relate settlement vioxx shareholder class action litigation note consolidated financial statement foreign exchange loss million relate devaluation company net monetary asset venezuela note consolidated financial statement low equity income azlp partially offset unfavorability item million loss extinguishment debt note consolidated financial statement million gain sale certain migraine clinical development program note consolidated financial statement million gain divestiture company remain ophthalmic business international market note consolidated financial statement high equity income certain research investment fund million goodwill impairment charge relate company joint venture supera note consolidated financial statement income expense net billion income compare million expense drive primarily gain recognize note low foreign exchange loss venezuelan currency devaluation partially offset charge recognize related extinguishment debt goodwill impairment note low equity income azlp segment profit million pharmaceutical segment profit nonreportable segment profit income income taxis segment profit comprise segment sale standard cost certain operating expense directly incur segment component equity income loss affiliate certain depreciation amortization expense internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit acquisition divestiturerelated cost include amortization purchase accounting adjustment intangible asset impairment charge restructure cost taxis pay joint venture level portion equity income additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item include gain divestiture net charge relate settlement vioxx shareholder class action litigation gain astrazenecas option exercise foreign exchange loss relate devaluation company net monetary asset venezuela loss extinguishment debt additional year expense relate health care reform fee reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale pharmaceutical segment profit decline compare primarily reflect unfavorable effect foreign exchange pharmaceutical segment profit decline compare drive primarily unfavorable effect product divestiture loss market exclusivity certain product partially offset cost saving productivity measure decline segment profit reflect termination company relationship azlp divestiture mcc table content taxis income effective income tax rate reflect impact acquisition divestiturerelated cost restructure cost partially offset beneficial impact foreign earning effective income tax rate reflect favorable impact net benefit million relate settlement certain federal income tax issue impact net charge relate settlement vioxx shareholder class action litigation fully deductible combine federal state tax rate favorable impact tax legislation enact fourth quarter unfavorable effect nontax deductible foreign exchange loss relate venezuela note consolidated financial statement effective income tax rate reflect impact gain divestiture mcc tax combine federal state tax rate addition effective income tax rate include net tax benefit million record connection astrazenecas option exercise note consolidated financial statement benefit approximately million associate capital loss generate connection sale sirna note consolidated financial statement effective income tax rate include unfavorable impact additional year expense nontax deductible health care reform fee company record accordance final regulation issue quarter irs effective income tax rate reflect net benefit million settlement certain federal income tax issue net benefit reduction tax reserve expiration applicable statute limitation favorable impact tax legislation enact quarter extend tax credit outof period net tax benefit approximately million associate resolution previously disclose legacy scheringplough federal income tax issue note consolidated financial statement company examination numerous tax authority jurisdiction globally ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure item currently discussion irs relate examination company conclude position sustain audit item result unfavorable outcome settlement material adverse impact company financial position liquidity result operation net income attributable noncontrolle interest net income attributable noncontrolle interest million million million decline compare reflect termination company relationship azlp result retirement kbi prefer stock note consolidated financial statement addition include portion intangible asset goodwill impairment charge relate company joint venture supera note consolidated financial statement attributable noncontrolle interest net income earning common share net income attributable merck inc billion billion billion eps nongaap income nongaap ep nongaap income nongaap eps alternative view company performance management merck provide management believe information enhance investor understand company result nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consist acquisition divestiturerelate cost restructure cost certain item exclude item significant component understand assess financial performance information nongaap income nongaap eps consider addition lieu net income ep prepared accordance generally accept accounting principle united states gaap additionally nongaap income non gaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation similar measure company table content nongaap income nongaap eps important internal measure company senior management receive monthly analysis operating result include nongaap income nongaap ep performance company measure basis performance metric senior management annual compensation derive nongaap income nongaap ep reconciliation gaap financial measure nongaap financial measure follow million share amount pretax income report gaap increase decrease exclude item acquisition divestiturerelated cost restructure cost item foreign currency devaluation relate venezuela net charge relate settlement vioxx shareholder class action litigation gain sale certain migraine clinical development program gain divestiture certain ophthalmic product gain divestiture merck consumer care gain astrazeneca option exercise loss extinguishment debt additional year expense health care reform fee taxis income report gaap estimate tax benefit provision exclude item net tax benefit settlement federal income tax issue tax benefit relate sale sirna therapeutics inc subsidiary nongaap net income net income attributable noncontrolle interest report gaap acquisition divestiturerelate cost attributable noncontrolle interest nongaap net income attributable merck inc eps assume dilution report gaap ep difference nongaap ep assume dilution include net benefit million record connection astrazeneca option exercise represent difference calculate gaap ep calculate nongaap eps different calculate dividing impact exclude item weightedaverage share applicable year acquisition divestiturerelate cost nongaap income nongaap eps exclude impact certain amount record connection acquisition divestiture amount include amortization intangible asset amortization purchase accounting adjustment inventory intangible asset impairment charge expense income relate change estimate fair value measurement contingent consideration exclude integration transaction certain cost associate business acquisition include severance cost table content company formal restructuring program transaction certain cost relate divestiture cost consider non recur management exclude amount nongaap income nongaap eps believe helpful understanding performance continue business restructuring cost nongaap income nongaap eps exclude cost relate restructuring action note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life site base anticipate date site close divest depreciation expense determine utilize useful life prior restructure action restructure cost include asset abandonment shut relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation cost company undertake restructuring different type cover period charge consider nonrecurre management exclude amount nongaap income nongaap eps believe helpful understanding performance continue business certain item nongaap income nongaap eps exclude certain item item represent substantive unusual item evaluate individual basis evaluation consider quantitative qualitative aspect unusual nature generally represent item result nature magnitude management anticipate occur company normal business regular basis exclude nongaap income nongaap eps foreign exchange loss relate devaluation company net monetary asset venezuela note consolidated financial statement net charge relate settlement vioxx shareholder class action litigation note consolidated financial statement gain sale certain migraine clinical development program note consolidated financial statement gain divestiture company remain ophthalmic business international market note consolidated financial statement net tax benefit relate settlement certain federal income tax issue note consolidated financial statement exclude nongaap income nongaap ep certain gain include gain divestiture mcc note consolidated financial statement gain recognize conjunction astrazeneca option exercise include related net tax benefit transaction note consolidated financial statement gain divestiture certain ophthalmic product international market note consolidated financial statement loss extinguishment debt note consolidated financial statement additional year expense relate health care reform fee discuss tax benefit sale sirna tax benefit settlement certain federal income tax issue note consolidated financial statement research development chart reflect company current research pipeline february set forth item business research development research development update company currently candidate regulatory review united states internationally keytruda fdaapprove antipd program death receptor therapy clinical development expand indication different cancer type keytruda currently approve treatment melanoma advanced melanoma nsclc pharmaceutical segment december merck announce result pivotal keynote study evaluate potential immunotherapy compare chemotherapy base prospective measurement pdl expression patient advance nsclc phase study keytruda significantly improve overall survival compare chemotherapy patient level pdl expression base datum merck submit supplemental biologic license application fda file marketing authorization application ema table content november merck announce fda grant breakthrough therapy designation keytruda treatment patient microsatellite instability high metastatic colorectal cancer fda breakthrough therapy designation intend expedite development review candidate plan use combination treat lifethreatening disease condition preliminary clinical evidence indicate drug demonstrate substantial improvement exist therapy clinically significant endpoint keytruda previously grant breakthrough therapy status advanced melanoma advanced nsclc keytruda clinical development program consist clinical trial include trial combine keytruda cancer treatment study encompass cancer type include bladder colorectal esophageal gastric head neck melanoma multiple myeloma non smallcell lung triple negative breast currently phase clinical development bezlotoxumab investigational antitoxin prevention difficile infection recurrence currently review fda ema january merck announce fda accept review biologic license application bla bezlotoxumab grant priority review prescription drug user fee act action date july september merck announce pivotal phase clinical study bezlotoxumab meet primary efficacy endpoint reduction difficile recurrence week compare placebo conjunction standard care antibiotic treatment difficile company seek approval intend file canada currently therapie approve prevention recurrent disease cause difficile insulin glargine candidate treatment patient type type diabete develop collaboration samsung bioepis december company submit application regulatory approval plan submit fda mka zepatier currently review treatment chronic hcv oncedaily fixeddose combination tablet contain nsa inhibitor elbasvir nsa protease inhibitor grazoprevir zepatier approve fda january treatment adult patient chronic hcv infection ribavirin investigational pediatric hexavalent combination vaccine dtapipvhibhepb review fda develop approve commercialize partnership merck sanofi pasteur vaccine design help protect important disease diphtheria tetanus pertussis whooping cough polio poliovirus type invasive disease cause haemophilus influenzae type hib hepatitis november fda issue crl respect bla company review crl plan communication fda february grant marketing authorization prophylaxis diphtheria tetanus pertussis hepatitis poliomyelitis invasive disease cause hib infant toddler age week market vaxeli spmsd company joint venture sanofi pasteur addition candidate regulatory review company drug candidate phase clinical development addition keytruda program discuss company anticipate file application regulatory approval fda respect certain candidate include note odanacatib oral onceweekly investigational treatment patient osteoporosis osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis september merck announce datum pivotal phase fracture outcomes study odanacatib postmenopausal woman osteoporosis longterm odanacatib fracture trial loft odanacatib meet primary endpoint significantly reduce risk type osteoporotic fracture radiographicallyassesse vertebral clinical hip clinical nonvertebral compare placebo reduce risk secondary endpoint clinical vertebral fracture addition treatment odanacatib lead progressive increase year bone mineral density lumbar spine total hip rate adverse event overall loft generally balanced patient table content take odanacatib placebo adjudicate event morphealike skin lesion atypical femoral fracture occur odanacatib group placebo group adjudicate major adverse cardiovascular event generally balance overall treatment group numerically adjudicate stroke event odanacatib placebo adjudicate atrial fibrillation report odanacatib group placebo group numeric imbalance mortality observe numeric difference appear related particular reported cause cause death merck continue collect datum blind extension study plan additional analysis datum trial include independent readjudication major adverse cardiovascular event mace support regulatory submission merck plan submit new drug application nda fda odanacatib follow completion independent adjudication analysis mace merck plan submit application ema ministry health labour welfare japan omarigliptin investigational onceweekly dpp inhibitor development treatment adult type diabete september company announce omarigliptin achieve primary efficacy endpoint phase study omarigliptin find noninferior januvia reduce patient estimate person blood glucose twoto threemonth period level baseline similar reduction achieve group headtohead study design evaluate onceweekly treatment omarigliptin compare januvia daily result present oral session european association study diabete annual meeting september merck announce japanese pharmaceutical medical device agency approve marizev omarigliptin tablet japan country approve omarigliptin merck plan submit omarigliptin regulatory approval united states worldwide regulatory submission follow ertugliflozin investigational oral sglt inhibitor evaluate treatment type diabete collaboration pfizer inc ertugliflozin study combination januvia sitagliptin metformin merck expect submit application regulatory approval united states ertugliflozin fixeddose combination tablet end investigational allergy immunotherapy tablet house dust mite allergy north america partnership merck alkabello merck plan submit nda fda half verubecestat merck novel investigational oral amyloid precursor protein sitecleave enzyme bace inhibitor treatment alzheimer disease study phase trial apec design evaluate safety efficacy versus placebo patient amnestic mild cognitive impairment alzheimer disease know prodromal alzheimer disease study phase randomize placebocontrolle study patient mildtomoderate alzheimer disease epoch epoch study complete enrollment fourth quarter estimate reach primary trial completion mid anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raise hdlc reduce ldl anacetrapib evaluate patient eventdriven cardiovascular clinical outcome trial sponsor oxford university reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease project conclude early november merck announce datum monitor committee dmc reveal outcomes study complete planned review unblinde study datum recommend study continue change dmc review safety efficacy datum study include assessment futility merck remain blind actual result analysis reveal safety efficacy datum reveal steer committee merck continue monitor progress study additional interim efficacy analysis plan mka combination relebactam investigational betalactamase inhibitor imipenemcilastatin approve carbapenem antibiotic fda designate combination qualified infectious disease product designate fast track status treatment hospitalacquire bacterial pneumonia ventilatorassociate bacterial pneumonia complicated intraabdominal infection complicate urinary tract infection table content letermovir investigational oral oncedaily antiviral candidate prevention treatment human cytomegalovirus infection letermovir receive orphan drug status united states grant fast track designation mkb refer generation ring investigational combination etonogestrel estradiol vaginal ring contraception treatment dysmenorrhea woman seek contraception mkj investigational fixeddose combination sitagliptin ipragliflozin development commercialization japan collaboration astellas pharma inc astella ipragliflozin sglt inhibitor codevelope astellas kotobuki pharmaceutical ltd kotobuki approve use japan copromote merck kotobuki investigational rvsvzebov ebola vaccine candidate study large scale phase clinical trial currently underway west africa november merck newlink genetic announce exclusive licensing collaboration agreement investigational ebola vaccine december merck announce application emergency use assessment list eual accept review world health organization accord eual process design expedite availability vaccine need public health emergency outbreak ebola procedure intend assist united nations procurement agency member state acceptability vaccine candidate emergencyuse set eual designation prequalification special procedure implement outbreak disease high rate morbidity andor mortality lack treatment andor prevention option instance recommend make vaccine available limited time clinical trial datum gather formal regulatory agency review national regulatory authority decision grant eual status base datum quality safety efficacyeffectiveness riskbenefit analysis emergency use eual designation allow emergency use vaccine remain investigational license commercial distribution inactivated varicella zoster virus vaccine development prevention herpe zoster company conduct phase trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy doravirine investigational oncedaily oral nextgeneration nonnucleoside reverse transcriptase inhibitor develop merck treatment hiv infection company divest discontinued certain drug candidate july merck allergan plc allergan enter agreement pursuant allergan acquire exclusive worldwide right merck investigational small molecule oral cgrp receptor antagonist develop treatment prevention migraine note consolidated financial statement surotomycin investigational oral antibiotic development treatment difficile associate diarrhea merck acquire surotomycin purchase cubist second quarter company receive unfavorable efficacy datum randomize doubleblinde activecontrolled study patient difficile associate diarrhea evaluation datum combine assessment commercial opportunity surotomycin result discontinuation program iprd impairment charge note consolidated financial statement bevenopran oral investigational therapy development potential treatment opioidinduce constipation patient chronic noncancer pain merck acquire bevenopran purchase cubist company decision continue development program seek outlicense asset corifollitropin alfa injection investigational fertility treatment control ovarian stimulation woman participate assist reproductive technology july merck receive crl fda nda corifollitropin alfa injection merck decision discontinue development corifollitropin alfa injection united states business reason corifollitropin alfa injection market elonva certain market outside united states table content company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologic capability company commit make externally source program great component pipeline strategy renew focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company review pipeline examine candidate provide value outlicense company continue evaluate certain latestage clinical development platform technology asset determine outlicense sale potential company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease neurodegenerative disease osteoporosis respiratory disease womens health acquire inprocess research development connection acquisition company record fair value inprocess research project time acquisition reach technological feasibility december balance iprd billion billion relate clinical development program company acquire acquisition idenix pharmaceuticals inc idenix approximately million million million respectively iprd project receive marketing approval major market company begin amortize asset base estimate useful life iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally certain iprd program fail abandon development company realize future cash flow estimate record iprd acquisition date company recover research development expenditure acquisition develop program circumstance occur company future operating result adversely affect company recognize impairment charge charge material company record million iprd impairment charge research development expense million relate surotomycin clinical development program obtain connection acquisition cubist company receive unfavorable efficacy datum clinical trial surotomycin evaluation datum combine assessment commercial opportunity surotomycin result discontinuation program iprd impairment charge note company record million iprd impairment charge primarily result change cash flow assumption certain compound obtain connection supera joint venture discontinuation certain animal health program company record million iprd impairment charge million relate writeoff intangible asset associate preladenant result discontinuation clinical development program compound addition company record impairment charge result change cash flow assumption certain compound pipeline program previously deprioritize subsequently deem alternative use period additional research development require remain program reach technological feasibility cost complete research project depend project bring table content final stage development ultimately submit fda regulatory agency approval december estimate cost complete project acquire connection acquisition phase development human health analogous stage development animal health approximately million acquisition research collaboration license agreement merck continue remain focused pursue opportunity potential drive near longterm growth certain recent significant transaction describe merck actively monitor landscape growth opportunity meet company strategic criterion january merck acquire iomet privately hold ukbased drug discovery company focus development innovative medicine treatment cancer particular emphasis field cancer immunotherapy cancer metabolism total purchase consideration transaction include upfront cash payment million future additional milestone payment million contingent certain clinical regulatory milestone achieve acquisition provide merck iomet preclinical pipeline ido indoleaminedioxygenase tdo tryptophan dioxygenase dualacte idotdo inhibitors company process determine preliminary fair value asset acquire liability assume total consideration transfer business acquisition transaction close january accordingly result operation acquire business include company result operation begin date july merck acquire ccam privately hold biopharmaceutical company focus discovery development novel cancer immunotherapy acquisition provide merck ccam lead pipeline candidate novel monoclonal antibody target immune checkpoint protein ceacam evaluate phase study treatment advanced recurrent malignancy include melanoma nonsmallcell lung bladder gastric colorectal ovarian cancer total purchase consideration transaction million include upfront payment million cash future additional payment million associate attainment certain clinical development regulatory commercial milestone company determine fair value million acquisition date transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date merck recognize intangible asset iprd million net asset million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect stage development project associate probability successful completion asset probabilityadjuste future net cash flow discount present value discount rate fair value contingent consideration determine utilize probabilityweighte estimate cash flow stream adjust expect timing payment utilize discount rate actual cash flow likely different assumed transaction close july accordingly result operation acquire business include company result operation begin date february merck ngm privately hold biotechnology company enter multiyear collaboration research discover develop commercialize novel biologic therapy wide range therapeutic area collaboration include multiple drug candidate currently preclinical development ngm include evaluate treatment diabete obesity nonalcoholic steatohepatitis ngm lead research development exist preclinical candidate autonomy identify pursue discovery stage program discretion merck option license result ngm program follow human proof concept trial merck exercise option merck lead global product development commercialization result product approve term agreement merck upfront payment ngm million include research development expense purchase equity stake ngm million merck commit million fund ngms effort initial fiveyear term collaboration potential additional funding certain condition meet prior merck initiate phase study license program ngm elect receive milestone royalty payment certain case cofund development participate global cost revenue share arrangement table content agreement provide ngm option participate copromotion cofunde program united states merck option extend research agreement additional twoyear term party certain termination right agreement event uncure material breach party additionally merck certain termination right event occurrence certain define condition termination event depend circumstance party vary right obligation respect continued development commercialization compound discover agreement certain relate payment obligation january merck acquire cubist leader development therapy treat infection cause broad range bacteria total consideration billion note consolidated financial statement transaction close january accordingly result operation acquire business include company result operation begin date estimate fair value identifiable intangible asset relate currently market product determine income approach company estimate project net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize discount rate actual cash flow likely different assume significant intangible asset relate zerbaxa cubicin sivextro company record fair value incomplete research project surotomycin time acquisition reach technological feasibility alternative future use capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project fair value surotomycin determine income approach probabilityadjuste future net cash flow discount present value discount rate second quarter company receive unfavorable efficacy datum clinical trial surotomycin evaluation datum combine assessment commercial opportunity surotomycin result discontinuation program iprd impairment charge connection cubist acquisition liability record potential future consideration contingent achievement future salesbase milestone fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow change input result different fair value measurement select joint venture affiliate information astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right merck earn revenue base sale kbi product revenue million million primarily relate sale nexium prilosec addition merck earn certain partnership table content return azlp million million record equity income affiliate june astrazeneca exercise option purchase merck interest kbi million cash million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june defer recognize time income expense net contingency eliminate sale occur million million respectively defer income recognize bring cumulative defer income recognize december million remain exercise price million primarily represent multiple time merck average annual profit allocation partnership year prior exercise merck recognize million gain income expense net result astrazenecas option exercise company remain interest azlp redeem accordingly company recognize noncash gain approximately million income expense net result retirement billion kbi prefer stock note consolidated financial statement elimination company billion investment azlp million reduction goodwill transaction result net tax benefit million primarily reflect reversal defer taxis azlp investment balance result astrazeneca exercise option july company long record equity income azlp supply sale azlp terminate sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe sale joint venture product follow million gardasil influenza vaccine zostavax viral vaccine rotateq hepatitis vaccine vaccine simcere msd shanghai pharmaceutical ltd march merck simcere pharmaceutical ltd simcere execute restructuring agreement merck agree transfer ownership interest simcere msd shanghai pharmaceutical ltd joint venture simcere result merck deconsolidate joint venture record net loss million income expense net capital expenditure capital expenditure billion billion billion expenditure united states million million million depreciation expense billion billion billion billion billion billion respectively apply location united states total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement table content analysis liquidity capital resource merck strong financial profile enable fully fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operation total debt cash provide operating activity billion billion billion decline cash provide operating activity compare reflect approximately billion taxis pay divestiture mcc cash provide operating activity include payment company million connection settlement enhance litigation cash provide operating activity continue company primary source fund finance operating need capital expenditure portion treasury stock purchase dividend pay shareholder cash investing activity billion compare million primarily reflect cash receive divestiture mcc high cash receive disposition business connection astrazeneca option exercise cash acquisition cubist partially offset low purchase security investment high proceed sale security investment cash acquisition idenix cash payment formation collaboration bayer cash investing activity million compare billion reflect cash receive divestiture mcc disposition business cash receive connection astrazenecas option exercise partially offset high purchase low proceed sale security investment cash acquisition idenix cash payment formation collaboration bayer cash financing activity billion compare billion drive primarily high proceed issuance debt low payment debt low purchase treasury stock partially offset low proceed exercise stock option decrease shortterm borrowing cash financing activity billion compare billion drive primarily high payment debt low proceed issuance debt high purchase treasury stock decrease shortterm borrowing partially offset high proceed exercise stock option company record charge million relate devaluation net monetary asset venezuela large majority cash note consolidated financial statement december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment generally cash investment hold foreign subsidiary subject significant tax payment cash investment repatriate form dividend company record defer tax liability certain unremitte earning amount earn overseas expect indefinitely reinveste outside united states accrual taxis provide cash investment hold foreign subsidiary fluctuate variety factor include time receipt payment normal course business cash provide operating activity united states continue company primary source fund finance domestic operating need capital expenditure portion treasury stock purchase dividend pay shareholder table content company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt interest relate debt obligation vioxx shareholder class action settlement reserve unrecognize tax benefit operating lease include future bulk supply purchase company commit connection certain divestiture january million debt mature repay company anticipate receive insurance proceed approximately million partially fund liability note consolidated financial statement december company consolidated balance sheet reflect liability unrecognize tax benefit interest penalty billion include billion reflect current liability high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising amount reflect research development obligation include contingent milestone payment exclude research development obligation potential future funding commitment approximately million investment research venture capital fund loan payable current portion longterm debt reflect million longdate note subject repayment option holder require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute approximately million pension plan million international pension plan million postretirement benefit plan august company terminate exist credit facility enter billion fiveyear credit facility mature august facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility february merck issue billion aggregate principal senior unsecured note consist million principal float rate note million principal float rate note billion principal note billion aggregate principal note billion aggregate principal note billion aggregate principal note company portion net proceed offer billion repay commercial paper issue substantially finance company acquisition cubist remain net proceed general corporate purpose include repurchase company common stock repayment outstanding commercial paper borrowing debt maturity february company redeem billion legacy cubist debt acquire acquisition note consolidated financial statement december company file security registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee table content exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date company continue maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november board director declare quarterly dividend share company common stock payable january march mercks board director authorize additional purchase billion merck common stock treasury treasury stock purchase authorization time limit time openmarket transaction block transaction exchange privately negotiate transaction company purchase billion common stock million share treasury company approximately billion remain march share repurchase program company purchase billion billion common stock respectively previously authorize share repurchase program financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate primary objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate table content foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option value collar strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow weak dollar result net benefit market value merck hedge decline estimate million million december respectively uniform weaken dollar market value determine foreign exchange option pricing model hold factor exchange rate constant merck principally use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow primary objective balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level cash flow contract report operating activity consolidate statement cash flow sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly strengthen currency exposure company december income taxis decline approximately million million company net long receivable position relative major foreign currency consideration forward contract uniform strengthen dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow january venezuela designate hyperinflationary result local foreign operation remeasure dollar impact record result operation february venezuelan government devalue currency bolvar fuerte vef dollar vef dollar company recognize loss exchange approximately million result remeasurement local monetary asset liability new rate addition official rate vef dollar venezuelan government maintain official rate sistema complementario administracion divisas sicad sistema marginal divisas simadi sicad simadi average rate publish central bank venezuela december average exchange rate infer vef dollar vef dollar respectively historically venezuelan government indicate essential good include food medicine remain official rate vef dollar table content second quarter evaluation evolve economic condition venezuela volatility country combine decline transaction settle official rate company determine unlikely outstanding net monetary asset settle official rate accordingly second quarter company record charge million income expense net devalue net monetary asset venezuela represent company estimate dollar ultimately collect quarter company record additional exchange loss million reflect ongoing effect translate transaction net monetary asset consistent second quarter result deterioration economic condition venezuela continue decline transaction settle official rate fourth quarter company begin simadi rate report venezuelan operation company revalue remain net monetary asset simadi rate result additional charge fourth quarter million accordingly december company approximately million dollar equivalent simadi rate remain net monetary asset venezuelan entity large majority cash merck sale venezuela approximately million company reduce operation venezuela merck continue work government venezuela import essential medicine country result transition simadi rate fourth quarter purpose report venezuelan operation merck anticipate sales venezuela minimis company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment comprehensive income oci remain accumulated comprehensive income aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table million number interest rate total swap notional debt instrument par value debt swap hold note note note note note note note interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change table content swap contract cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting policy company consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement acquisition determine acquisition qualify business combination asset acquisition company make certain judgment include assessment input process output associate acquire set activity company determine acquisition consist input process apply input ability create output acquisition determine business combination business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition fair value intangible asset include acquire iprd determine utilize information available near acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck separate determination useful life asset begin amortization certain company business acquisition involve potential future payment consideration contingent achievement table content performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingent consideration liability remeasure current fair value change expense income record earning change input result significantly different fair value adjustment judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation company determine transaction account acquisition business transaction account acquisition asset business combination goodwill record asset acquisition acquire iprd alternative future use charge expense acquisition date fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate revenue recognition revenue sale product recognize title risk loss pass customer typically time delivery recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount customer collection account receivable expect excess year provision aggregate indirect customer discount cover chargeback rebate chargeback discount occur contract customer purchase directly intermediary wholesaler contract customer generally purchase product contract price plus markup wholesaler wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision base expect payment drive patient usage contract performance benefit provider customer company use historical customer segment mix adjust know event order estimate expect provision amount accrue aggregate indirect customer discount evaluate quarterly basis table content comparison information provide wholesaler health maintenance organization pharmacy benefit manager customer amount accrue adjustment record trend significant event indicate change estimate provision appropriate company continually monitor provision aggregate indirect customer discount material adjustment estimate associate aggregate indirect customer discount provision summarize information change aggregate indirect customer discount accrual relate sale follow million balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market additional generic competition change formulary launch overthecounter product product return provision pharmaceutical sale percentage net pharmaceutical sale distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide mention datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement table content inventory produce preparation product launch capitalize december million million respectively contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify accrue cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year table content sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weighted average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan net periodic benefit cost pension postretirement benefit plan total million million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset change net periodic benefit cost year year pension postretirement benefit plan largely attributable change discount rate affect net amortization company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december discount rate company pension postretirement benefit plan range compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset reference information company develop forward look return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return range range pension postretirement benefit plan company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement table content net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component aoci expect return pension plan base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize market relate value asset ratably fiveyear period net loss amount aoci excess certain threshold amortize net periodic benefit cost average remain service life employee restructure cost restructure cost record connection restructuring program design reduce cost structure increase efficiency enhance competitiveness result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect material production cost market administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business acquire assign reporting unit company test goodwill impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price additionally company evaluate extent fair value exceed carry value reporting unit date valuation perform company conclude likely fair value report unit carrying quantitative fair value test perform acquire intangible exclude iprd record fair value assign estimate useful life amortize primarily straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company test iprd impairment annually frequently impairment indicator exist assess qualitative factor determine likely fair value iprd intangible asset carrying company conclude likely table content fair value carrying quantitative test compare fair value iprd intangible asset carrying value perform impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize company operating result judgment evaluate impairment longlive intangible materially affect company result operation impairment investment company review investment impairment base determination decline market value investment carrying value otherthantemporary company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthan temporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci taxis income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operate estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability recently issue accounting standard financial accounting standard board fasb issue amend accounting guidance revenue recognition apply contract customer objective new guidance improve table content comparability revenue recognition practice entity provide useful information user financial statement improve disclosure requirement august fasb approve oneyear deferral effective date make guidance effective interim annual period begin report entity choose adopt standard original effective date company currently assess impact adoption consolidate financial statement april fasb issue accounting guidance require debt issuance cost present direct deduction carry debt balance sheet oppose present deferred charge new guidance effective interim annual period begin december company debt issuance cost record defer charge approximately million january fasb issue revise guidance accounting report financial instrument new guidance require equity investment readily determinable fair value currently classify available sale measure fair value change fair value recognize net income new guidance simplify impairment testing equity investment readily determinable fair value change certain disclosure requirement guidance effective interim annual period begin early adoption permit company currently assess impact adoption consolidate financial statement cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forward look statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income comprehensive income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck inc subsidiary year end december millions share amount sale cost expense material production marketing administrative research development restructuring cost income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder consolidate statement comprehensive income merck inc subsidiary year end december million net income attributable merck inc comprehensive income loss net taxis net unrealized loss gain derivative net reclassification net unrealized loss gain investment net reclassification benefit plan net gain loss prior service credit cost net amortization cumulative translation adjustment comprehensive income attributable merck inc accompany note integral consolidated financial statement table content consolidate balance sheet merck inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account exclude account receivable classified asset note inventory exclude inventory classify asset note current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck inc comprehensive income net tax cash dividend declare common stock share treasury stock share purchase supera joint venture formation net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive loss net tax cash dividend declare common stock share treasury stock share purchase astrazeneca option exercise net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive income net tax cash dividend declare common stock share treasury stock share purchase change noncontrolle ownership interest net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization intangible asset impairment charge foreign currency devaluation relate venezuela net charge relate settlement vioxx shareholder class action litigation gain divestiture merck consumer care business gain astrazeneca option exercise loss extinguishment debt equity income affiliate dividend distribution equity method affiliate defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security investment proceed sale security investment divestiture merck consumer care business net cash divest disposition business net cash divest proceed astrazeneca option exercise acquisition cubist pharmaceuticals inc net cash acquire acquisition idenix pharmaceuticals inc net cash acquire acquisition business net cash acquire acquisition bayer collaboration right cash inflow net investment hedge net cash investing activity cash flow financing activity net change shortterm borrowing payment debt proceed issuance debt purchase treasury stock dividend pay stockholder dividend pay proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement table content note consolidated financial statement merck inc subsidiarie million share amount nature operation merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product market directly joint venture company operation principally manage product basis comprise operating segment pharmaceutical animal health alliance healthcare service segment pharmaceutical segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer merck alliance segment primarily include result company relationship astrazeneca termination relationship june companys healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient january company acquire cubist pharmaceuticals inc cubist july merck acquire ccam biotherapeutics ltd ccam result cubist ccam business include merck financial statement subsequent respective acquisition date note october company divest consumer care segment develop manufacture market overthecounter foot care sun care product note summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis acquisition business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition company determine asset acquire meet table content definition business acquisition method accounting transaction account acquisition asset business combination goodwill record foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include accumulate comprehensive income loss aoci reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost market cost substantial majority domestic pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain inventory produce preparation product launch consider high probability regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt equity security classify availableforsale report fair value fair value company investment determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value consider temporary report net tax comprehensive income oci decline fair value equity security consider otherthan temporary impairment loss charge income expense net company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthantemporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci realize gain loss debt equity security include income expense net revenue recognition revenue sale product recognize title risk loss pass customer typically delivery recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount collection account receivable expect excess year accrual chargeback reflect direct reduction account receivable accrual rebate record current liability accrue balance relative provision chargeback rebate include account receivable accrue current liability million billion respectively december million billion respectively december company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission table content guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing depreciation expense billion billion billion advertising promotion cost advertising promotion cost expense incur company record advertising promotion expense billion billion billion respectively software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development capitalize software cost include property plant equipment amortize begin software project substantially complete asset ready intend use capitalize software cost associate project amortize year include company ongoing multiyear implementation enterprisewide resource planning system million million net accumulate amortization december respectively capitalize software cost amortize period range year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform acquire intangible acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year note company periodically evaluate current fact circumstance indicate carry value acquire intangible recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference carry value intangible asset fair value determine base net present value estimate future cash flow acquire inprocess research development acquire inprocess research development iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination useful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization company test iprd impairment annually frequently impairment indicator exist assess qualitative factor determine likely fair value iprd intangible asset carrying company conclude likely fair value carrying quantitative test compare fair value iprd intangible asset carrying value perform fair value carrying impairment loss recognize operating result contingent consideration certain company business acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event risk table content adjust discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingent consideration liability remeasure current fair value change expense income record earning change input result significantly different fair value adjustment research development research development expense incur upfront milestone payment party connection research development collaboration prior regulatory approval expense incur payment party subsequent regulatory approval capitalize amortize shorter remaining license product patent life amount collaborative partner relate development activity generally reflect reduction research development expense specific milestone achieve nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost iprd impairment charge period addition research development expense include expense income relate change estimate fair value measurement liability contingent consideration sharebase compensation company expense sharebased payment employee requisite service period base grantdate fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement employee termination cost accrue restructuring action probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income consolidate statement income use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation table content recently adopt accounting standard november financial accounting standard board fasb issue accounting guidance balance sheet classification defer taxis simplification initiative aim reduce complexity accounting standard new guidance require defer tax asset liability relate valuation allowance classify noncurrent balance sheet company elect early adopt new guidance fourth quarter note recently issue accounting standard fasb issue amend accounting guidance revenue recognition apply contract customer objective new guidance improve comparability revenue recognition practice entity provide useful information user financial statement improve disclosure requirement august fasb approve oneyear deferral effective date make guidance effective interim annual period begin report entity choose adopt standard original effective date company currently assess impact adoption consolidate financial statement april fasb issue accounting guidance require debt issuance cost present direct deduction carry debt balance sheet oppose present deferred charge new guidance effective interim annual period begin december company debt issuance cost record defer charge approximately million january fasb issue revise guidance accounting report financial instrument new guidance require equity investment readily determinable fair value currently classify available sale measure fair value change fair value recognize net income new guidance simplify impairment testing equity investment readily determinable fair value change certain disclosure requirement guidance effective interim annual period begin early adoption permit company currently assess impact adoption consolidate financial statement restructure restructure program company initiate action global restructuring program restructuring program global initiative sharpen commercial research development focus action program primarily include elimination position sale administrative headquarters organization research development additionally action include reduction company global real estate footprint improvement efficiency manufacture supply network company record total pretax cost million billion related restructuring program inception restructuring program december merck record total pretax accumulate cost approximately billion eliminate approximately position comprise employee separation elimination contractor vacant position action restructure program substantially complete end accordingly january remain accrue liability future separation restructure program combine remain accrue liability merger restructuring program remain activity program account aggregate prospectively merger restructure program subsequent merck scheringplough corporation scheringplough merger company commence action global restructuring program merger restructuring program design streamline cost structure combine company action program initiate action program primarily include elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility table content company record total pretax cost million million billion related restructuring program inception merger restructuring program december merck record total pretax accumulate cost approximately billion eliminate approximately position comprise employee separation elimination contractor vacant position nonfacility relate restructuring action merger restructuring program substantially complete accordingly note january remain accrue liability future separation restructure program combine remain accrue liability merger restructuring program remain activity program primarily relate ongoing facility rationalization account aggregate prospectively company expect complete action end incur approximately billion additional pretax cost company estimate approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest october company sell active pharmaceutical ingredient api manufacturing business include related manufacturing facility netherland aspen holding aspen plan manufacturing facility rationalization merger restructuring program connection sale aspen acquire certain brand product merck transfer aspen effective december consideration transaction include cash million note receivable present value million time disposition cash portion consideration company receive million fourth quarter remain million receive company january restructuring program merck announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness pretax cost million record related restructuring program segment report restructuring charge unallocated expense table content follow table summarize charges related restructuring program activity type cost separation accelerate year end december costs depreciation total restructuring program material production marketing administrative research development restructuring cost merger restructuring program material production marketing administrative research development restructuring cost year end december restructuring program material production marketing administrative research development restructuring cost merger restructuring program material production marketing administrative research development restructuring cost year end december restructuring program material production marketing administrative research development restructuring cost merger restructuring program material production marketing administrative research development restructuring cost restructure program material production marketing administrative restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate position eliminate restructure program approximately position eliminate merger restructuring program approximately position elimination comprise actual headcount reduction elimination contractor vacant position accelerate depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference table content depreciation expense recognize revise useful life site base anticipate date site close divest depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future undiscounte cash flow sufficient recover respective book value merck require accelerate depreciation site asset record impairment charge anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor activity include million million million respectively asset abandonment shutdown relate cost additionally activity include certain employeerelate cost associate pension postretirement benefit plan note share base compensation activity reflect net pretax loss result sale facility relate asset million million million primarily reflect loss transaction aspen discuss adjustment previously record amount material period follow table summarize charge spend relate restructuring activity program separation accelerate cost depreciation total restructuring program restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december merger restructuring program restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december nonfacility relate cash outlay associate restructure program merger restructuring program substantially complete end remain cash outlay expect substantially complete end acquisition divestiture research collaboration license agreement company continue strategy establish external alliance complement internal research capability include research collaboration license preclinical clinical compound drive near longterm growth company supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology arrangement include upfront payment expense reimbursement payment party milestone royalty profit share payment contingent occurrence certain future event link success asset development company review pipeline examine candidate provide value outlicense portfolio assessment process divest certain product table content acquisition cubist pharmaceuticals inc january merck acquire cubist leader development therapy treat infection cause broad range bacteria acquisition complement merck exist hospital acute care business total consideration transfer billion include cash pay outstanding cubist share billion sharebase compensation payment settle equity award attributable precombination service cash pay transaction cost behalf cubist sharebase compensation payment settle nonveste equity award attributable postcombination service recognize transaction expense addition company assume outstanding convertible debt cubist fair value approximately billion acquisition date merck redeem debt february transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date fair value asset acquire liability assume cubist follow cash cash equivalent account receivable inventory current asset property plant equipment identifiable intangible asset product product right year weightedaverage useful life iprd noncurrent asset current liability defer income tax liability longterm debt noncurrent liability total identifiable net asset goodwill consideration transfer include current liability noncurrent liability contingent consideration million million respectively goodwill recognize largely attributable anticipate synergy expect arise acquisition allocate pharmaceutical segment goodwill deductible tax purpose estimate fair value identifiable intangible asset relate currently market product determine income approach fair value estimate base market participant expectation asset discount project net cash flow company estimate project net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probability adjust future net cash flow product discount present value utilize discount rate actual cash flow likely different assume significant intangible asset relate zerbaxa cubicin sivextro note company record fair value incomplete research project surotomycin time acquisition reach technological feasibility alternative future use capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project fair value surotomycin determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect stage development project associate probability successful completion net cash flow table content discount present value discount rate second quarter company receive unfavorable efficacy datum clinical trial surotomycin evaluation datum combine assessment commercial opportunity surotomycin result discontinuation program iprd impairment charge note connection cubist acquisition liability record potential future consideration contingent achievement future salesbase milestone fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow change input result different fair value measurement transaction close january accordingly result operation acquire business include company result operation begin date cubist contribute sale billion merck revenue company long able provide result operation attributable cubist operation cubist largely integrate company incur million transaction cost directly relate acquisition cubist include sharebased compensation cost severance cost legal advisory fee reflect market administrative expense follow unaudited supplemental pro forma datum present consolidated information acquisition cubist complete january year end december sale net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder unaudite supplemental pro forma datum reflect historical information merck cubist adjust include additional amortization expense base fair value asset acquire additional interest expense incur borrowing fund acquisition transaction cost associate acquisition relate tax effect adjustment pro forma datum consider indicative result occur acquisition consummate january indicative future result transaction december company divest remain ophthalmic portfolio international market mundipharma ophthalmology product limited merck receive consideration approximately million recognize gain million record income expense net july merck acquire ccam privately hold biopharmaceutical company focus discovery development novel cancer immunotherapy acquisition provide merck ccam lead pipeline candidate novel monoclonal antibody target immune checkpoint protein ceacam evaluate phase study treatment advanced recurrent malignancy include melanoma nonsmallcell lung bladder gastric colorectal ovarian cancer total purchase consideration transaction million include upfront payment million cash future additional payment million associate attainment certain clinical development regulatory commercial milestone company determine fair value million acquisition date transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date merck recognize intangible asset iprd million net asset million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach asset probabilityadjuste future net cash flow discount present value discount rate table content fair value contingent consideration determine utilize probabilityweighte estimate cash flow stream adjust expect timing payment utilize discount rate actual cash flow likely different assumed transaction close july accordingly result operation acquire business include company result operation begin date pro forma financial information include ccams historical financial result significant compare company financial result july merck allergan plc allergan enter agreement pursuant allergan acquire exclusive worldwide right merck investigational small molecule oral calcitonin generelate peptide cgrp receptor antagonist develop treatment prevention migraine term agreement allergan acquire right upfront payment million million pay august close transaction million payable april merck additionally entitle receive potential development commercial milestone payment tiere doubledigit royalty base commercialization program allergan fully responsible development cgrp program manufacturing commercialization approval launch product company record gain million income expense net relate transaction february merck ngm biopharmaceuticals inc ngm privately hold biotechnology company enter multiyear collaboration research discover develop commercialize novel biologic therapy wide range therapeutic area collaboration include multiple drug candidate currently preclinical development ngm include evaluate treatment diabete obesity nonalcoholic steatohepatitis ngm lead research development exist preclinical candidate autonomy identify pursue discovery stage program discretion merck option license result ngm program follow human proof concept trial merck exercise option merck lead global product development commercialization result product approve term agreement merck upfront payment ngm million include research development expense purchase equity stake ngm million merck commit million fund ngms effort initial fiveyear term collaboration potential additional funding certain condition meet prior merck initiate phase study license program ngm elect receive milestone royalty payment certain case cofund development participate global cost revenue share arrangement agreement provide ngm option participate promotion cofunded program united states merck option extend research agreement additional twoyear term party certain termination right agreement event uncure material breach party additionally merck certain termination right event occurrence certain define condition termination event depend circumstance party vary right obligation respect continued development commercialization compound discover agreement certain relate payment obligation december merck acquire oncoethix privately hold biotechnology company specialize oncology drug development total purchase consideration transaction million include upfront cash payment million future additional milestone payment million contingent certain clinical regulatory milestone achieve company determine fair value million acquisition date transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date merck recognize intangible asset iprd million relate otx investigational novel oral bet bromodomain inhibitor currently phase study treatment hematological malignancy advance solid tumor liability contingent consideration million net asset million fair value identifiable intangible asset relate iprd determine income approach asset probabilityadjuste future net cash flow discount present value discount rate fair value contingent consideration determine utilize probabilityweighte estimate cash flow stream adjust expect timing payment utilize discount rate actual cash flow likely different assumed transaction close december accordingly result operation acquire business include company result operation begin date pro forma table content financial information include oncoethixs historical financial result significant compare company financial result october company complete sale merck consumer care mcc business bayer bayer billion billion net cash divest customary closing adjustment certain contingent amount hold payable manufacturing site transfer canada regulatory approval korea term agreement bayer acquire merck exist overthecounter business include global trademark prescription right claritin afrin company recognize pretax gain sale mcc billion october company enter worldwide clinical development collaboration bayer market develop portfolio soluble guanylate cyclase sgc modulator include bayers adempas riociguat member novel class compound adempas approve treat pulmonary arterial hypertension pah approve patient chronic thromboembolic pulmonary hypertension cteph adempas market united states europe pah cteph japan cteph company equally share cost profit collaboration implement joint development commercialization strategy collaboration include clinical development bayer vericiguat currently phase trial worsen heart failure optin right earlystage sgc compound development bayer merck turn available early stage sgc compound similar term return broad collaboration right merck upfront payment bayer billion potential additional milestone payment billion achievement agreedupon sale goal adempas bayer continue lead commercialization america merck lead commercialization rest world vericiguat potential optin product bayer lead rest world merck lead america product candidate include agreement company share development cost profit sale right copromote territory lead company determine merck payment access bayer compound constitute acquisition asset billion consideration pay merck million fair value relate adempas capitalize intangible asset subject amortization estimate useful life year remain million fair value relate vericiguat compound clinical development expense research development expense fair value adempas vericiguat determine income approach fair value estimate base probabilityadjuste future net cash flow vericiguat stage development project associate probability successful completion net cash flow discount present value discount rate adempas vericiguat future sale base milestone accrue probable achieve related intangible asset recognize amortize material production cost applicable useful life company bayer right terminate agreement cause productbyproduct basis product develop commercialize agreement adempas bayer termination right event party material uncured breach relate product september merck sun pharmaceutical industries ltd sun pharma enter exclusive worldwide licensing agreement merck investigational therapeutic antibody candidate tildrakizumab treatment chronic plaque psoriasis skin ailment term agreement sun pharma acquire worldwide right tildrakizumab use human indication merck exchange upfront payment million merck continue clinical development regulatory activity fund sun pharma product approval sun pharma responsible regulatory activity include subsequent submission pharmacovigilance post approval study manufacturing commercialization approve product merck eligible receive future payment associate regulatory include product approval sale milestone tiere royalty range midsingle digit teen percentage rate sale merck record loss million transaction include income expense net august merck complete acquisition idenix pharmaceuticals inc idenix approximately billion cash billion net cash acquire idenix biopharmaceutical company engage discovery development medicine treatment human viral disease primary focus development nextgeneration oral antiviral therapeutic treat hepatitis virus hcv infection transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date merck recognize intangible asset iprd billion relate table content idx net defer tax liability million net liability million nucleotide prodrug phase clinical development evaluate potential inclusion development oral pangenotypic fixeddose combination regimen excess consideration transfer fair value net asset acquire billion record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach asset probabilityadjuste future net cash flow discount present value discount rate actual cash flow likely different assumed transaction close august accordingly result operation acquire business include company result operation begin date pro forma financial information include idenixs historical financial result significant compare company financial result merck enter agreement sell certain ophthalmic product santen pharmaceutical ltd santen japan markets europe asia pacific agreement provide upfront payment santen additional payment base define sale milestone santen purchase supply ophthalmology product cover agreement fiveyear period transaction closed market july remain market october company receive million upfront payment santen net certain adjustment recognize gain million transaction include income expense net march merck divest sirna therapeutics inc sirna subsidiary alnylam pharmaceuticals inc alnylam consideration million share alnylam common stock merck eligible receive future payment associate achievement certain regulatory commercial milestone royaltie future sale merck record gain million income expense net relate transaction excess merck tax basis investment sirna value receive result approximate million tax benefit record january merck sell marketing right saphris antipsychotic indicate treatment schizophrenia bipolar disorder adult forest laboratories inc forest term agreement forest upfront payment million record sale additional payment merck base define sale milestone addition transaction merck agree supply product forest subsequently acquire allergan patent expiry february merck supera farma laboratorio supera brazilian pharmaceutical company coowne cristlia eurofarma establish joint venture market distribute sell portfolio pharmaceutical brand generic product merck cristlia eurofarma brazil merck own joint venture cristlia eurofarma collectively transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value result merck recognize intangible asset currently market product million iprd million goodwill million defer tax liability million company record increase noncontrolle interest paidin capital amount million million respectively transaction close february accordingly result operation acquire business include company result operation begin date company record certain intangible asset impairment charge related supera joint venture note remicadesimponi subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company marketing right product europe russia turkey scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis auto injector delivery system european commission approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial table content sale simponi european union follow receipt pricing reimbursement approval remicade lose market exclusivity major european market february company long market exclusivity marketing territory company continue market exclusivity simponi marketing territory profit derive merck distribution product country equally divide merck financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate primary objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option value collar strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow table content fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge effective portion unrealize gain loss contract record aoci reclassify sale hedge anticipate revenue recognize hedge relationship highly effective hedge ineffectiveness minimis derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose primary objective balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level cash flow contract report operating activity consolidate statement cash flow monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment oci remain aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci include cumulative translation adjustment pretax gain million million pretax loss million eurodenominate note interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table table content number interest rate total swap notional debt instrument par value debt swap hold note note note note note note note interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative derivative dollar dollar balance sheet caption asset liability notional asset liability notional derivative designate hedge instrument interest rate swap contract noncurrentother asset interest rate swap contract current accrue current liability interest rate swap contract noncurrentother noncurrent liability foreign exchange contract current current asset foreign exchange contract noncurrent asset foreign exchange contract current accrue current liability derivative designate hedge instrument foreign exchange contract current current asset foreign exchange contract noncurrent asset foreign exchange contract current accrue current liability foreign exchange contract noncurrent noncurrent liability table content note company record derivative gross basis consolidated balance sheet company master netting agreement financial institution counterpartie concentration credit risk follow table provide information company derivative position subject master netting arrangement present net basis allow right offset counterparty cash collateral exchange master agreement relate credit support annexe december asset liability asset liability gross amount recognize consolidated balance sheet gross subject offset master netting arrangement offset consolidated balance sheet cash collateral receive post net amount table provide information location pretax gain loss amount derivative designate fair value hedge relationship designate foreign currency cash flow hedging relationship iii designate foreign currency net investment hedge relationship designate hedge relationship year end december derivative designate fair value hedge relationship interest rate swap contract gain loss recognize income expense net derivative loss gain recognize income expense net hedge item derivative designate foreign currency cash flow hedging relationship foreign exchange contract gain loss reclassify aoci sale gain recognize oci derivative derivative designate foreign currency net investment hedging relationship foreign exchange contract gain recognize income expense net derivative gain recognize oci derivative derivative designate hedge relationship foreign exchange contract gain loss recognize income expense net derivative gain loss recognize sale million million million ineffectiveness hedge respectively ineffectiveness hedge represent exclude hedge effectiveness testing derivative contract mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate december company estimate million pretax net unrealize gain derivative mature month hedge foreign currency denominate sale period reclassify aoci sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information availableforsale investment december follow gross unrealized gross unrealize fair amortize fair amortize value cost gain loss value cost gain loss corporate note bond commercial paper government agency security assetbacke security mortgagebacke security foreign government bond equity security availableforsale debt security include shortterm investment total billion december remain debt security billion mature year december debt security pledge collateral fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset liability value determine pricing model discount cash flow methodology similar technique significant unobservable input asset liabilitie determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset investment corporate note bond commercial paper government agency security assetbacke security mortgagebacke security foreign government bond equity security asset security hold employee compensation derivative asset purchase currency option forward exchange contract interest rate swap total asset liability liabilitie contingent consideration derivative liability forward exchange contract write currency option interest rate swap total liability primarily assetbacke security highlyrate standard poor rate aaa moodys investor service rating aaa secure primarily credit card auto loan home equity receivables weightedaverage live primarily year mortgagebacked security represent aaarate security issue unconditionally guarantee payment principal interest government agency fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant transfer level level december cash cash equivalent billion include billion cash equivalent consider level fair value hierarchy table content contingent consideration summarize information change liabilitie contingent consideration follow fair value january change fair value addition payment fair value december record research development expense material production cost company recognize liability contingent consideration million relate acquisition cubist million relate acquisition ccam note addition company pay million contingent consideration relate commercial sale zerbaxa united states fair value liability contingent consideration relate acquisition occur increase million result progression program preclinical phase increase result high fair value future regulatory milestone royalty payment increase probability success program give progression phase addition company recognize liability million contingent consideration relate acquisition oncoethix note fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline majority company account receivable arise product sale united states europe primarily drug wholesaler retailer hospital government agency manage health care provider pharmacy benefit manager company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor economic condition include volatility associate international sovereign economy associate impact financial market business take consideration global economic condition ongoing sovereign debt issue certain european country december asset include million million respectively account receivable expect collect year december company total net account receivable outstanding year approximately million company expect writeoff adjustment account receivable material adverse effect financial position liquidity result operation company customer large account receivable balance amerisourcebergen corporation cardinal health inc mckesson corporation zuellig pharma ltd asia pacific aah pharmaceuticals ltd represent aggregate approximately onethird total account receivable december company monitor creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale table content derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty december company receive cash collateral million billion respectively counterpartie obligation return collateral record accrue current liability company advanced cash collateral counterpartie december inventory inventory december consist finished good raw material work process supply total approximate current cost increase lifo cost recognize inventory asset inventory value lifo method comprise approximately billion billion inventory december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch goodwill intangible follow table summarize goodwill activity segment pharmaceutical total balance january acquisition divestiture impairment balance december acquisition divestiture impairment balance december include cumulative translation adjustment goodwill balance certain adjustment accumulate goodwill impairment loss december million million respectively addition goodwill pharmaceutical segment result primarily acquisition cubist note reduction pharmaceutical segment goodwill result divestiture company remain ophthalmic business international market note impairment goodwill nonreportable segment relate primarily certain business healthcare service segment table content addition goodwill pharmaceutical segment primarily result acquisition idenix reduction result sale mcc divestiture certain ophthalmic product international market note reduction goodwill segment result termination company relationship astrazeneca azlp note divestiture mcc quarter company record impairment charge goodwill relate supera joint venture result change cash flow assumption certain compound currently market product intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right inprocess research development tradename acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life increase intangible asset product product right primarily relate acquisition cubist note company significant acquire intangible relate market product include product product right december include zerbaxa billion zetia billion vytorin billion sivextro billion implanonnexplanon million dificid million nuvare million nasonex million cubicin million company recognize intangible asset related adempas result formation collaboration bayer note carry value million december reflect table company record impairment charge relate market product intangible million billion million respectively material production cost charge primarily relate impairment customer relationship tradename intangible certain business healthcare service segment record million relate pegintron million relate victrelis million relate rebetol product market company treatment chronic hcv infection sale product adversely affect loss market share patient treatment delay market anticipate availability new therapeutic option trend accelerate rapidly previously anticipate company addition development competitive hcv treatment market lead market share loss great company predict factor cause change cash flow projection pegintron victrelis rebetol indicate intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate pegintron victrelis rebetol compare related carry value result impairment charge note impairment charge record million result low cash flow projection saphrissycrest reduce expectation international markets united states revision cash flow indicate saphrissycr intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption consider different scenario determine good estimate fair value intangible asset relate saphrissycrest compare related carrying value result impairment charge note remain million impairment charge result low cash flow projection rebetol reduce expectation japan europe revision cash flow indicate rebetol intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate rebetol compare related carrying value result impairment charge note iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount table content capitalize iprd account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project company separate determination useful life asset begin amortization million million million respectively iprd reclassify product product right receipt marketing approval major market company record million iprd impairment charge research development expense million relate surotomycin clinical development program obtain connection acquisition cubist company receive unfavorable efficacy datum clinical trial surotomycin evaluation datum combine assessment commercial opportunity surotomycin result discontinuation program iprd impairment charge note company record million iprd impairment charge primarily result change cash flow assumption certain compound obtain connection supera joint venture discontinuation certain animal health program company record million iprd impairment charge million relate writeoff intangible asset associate preladenant result discontinuation clinical development program compound addition company record impairment charge result change cash flow assumption certain compound pipeline program previously deprioritize subsequently deem alternative use period iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate company recognize additional noncash impairment charge future relate market product pipeline program charge material aggregate amortization expense primarily record material production cost billion billion billion estimate aggregate amortization expense year follow billion billion billion billion billion joint venture equity method affiliate equity income affiliate reflect performance company joint venture equity method affiliate include sanofi pasteur msd certain investment fund azlp termination company relationship azlp june discuss equity income affiliate million million million include income expense net note investment affiliate account equity method include joint venture total million december million december amount report asset amount joint venture include current asset million december million december astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange table content general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right merck earn revenue base sale kbi product revenue million million primarily relate sale nexium prilosec addition merck earn certain partnership return azlp million million record equity income affiliate june astrazeneca exercise option purchase merck interest kbi million cash million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june defer recognize time income expense net contingency eliminate sale occur million million respectively defer income recognize bring cumulative defer income recognize december million remain exercise price million primarily represent multiple time merck average annual profit allocation partnership year prior exercise merck recognize million gain income expense net result astrazenecas option exercise company remain interest azlp redeem accordingly company recognize noncash gain approximately million income expense net result retirement billion kbi prefer stock note elimination company billion investment azlp million reduction goodwill transaction result net tax benefit million primarily reflect reversal defer taxis azlp investment balance result astrazeneca exercise option july company long record equity income azlp supply sale azlp terminate summarize financial information azlp follow year end december sale material production cost expense net income taxis include result june termination date merck partnership return azlp generally contractually determine note base percentage income azlp respect mercks limited partnership interest sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale million billion billion loan payable longterm debt commitment loan payable december include billion note million shortterm foreign borrowing million longdate note subject repayment option holder loan payable december include billion note billion commercial paper million shortterm foreign borrowing million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing year end december respectively table content longterm debt december consist note note note note note note note note eurodenominate note eurodenominate note note floatingrate borrow note note note floatingrate note note eurodenominate note note note note debenture debenture floatingrate note debenture note note floatingrate borrowing present table include million million december respectively borrowing variable rate result effective interest rate zero include foreign borrowing million million december respectively vary rate respectively exception debenture note list table redeemable merck option time vary redemption price february merck issue billion aggregate principal senior unsecured note consist million principal float rate note million principal float rate note billion principal note billion aggregate principal note billion aggregate principal note billion aggregate principal note company portion net proceed offer billion repay commercial paper issue substantially finance company acquisition cubist remain net proceed general corporate purpose include repurchase company common stock repayment outstanding commercial paper borrowing debt maturity february company redeem billion legacy cubist debt acquire acquisition note table content october company issue billion principal senior unsecured note net proceed offer billion repay debt validly tender connection tender offer launch company certain outstanding note debenture company pay billion aggregate consideration applicable purchase price accrue interest redeem billion principal debt november merck redeem additional billion principal senior unsecured note company record pretax loss million connection transaction effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date certain company borrowing require merck comply financial covenant include requirement total debt capitalization ratio define applicable agreement exceed december company compliance covenant aggregate maturity longterm debt year follow billion million billion billion billion august company terminate exist credit facility enter billion fiveyear credit facility mature august facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility rental expense operating lease net sublease income million million million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include environmental matter opinion company unlikely resolution matter material company financial position result operation cash flow give nature litigation discuss complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation settlement posture party litigation factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability effective august table content vioxx litigation product liability lawsuit previously disclose merck defendant approximately active federal state lawsuit vioxx product liability lawsuit allege personal injury result use vioxx case coordinate multidistrict litigation district court eastern district louisiana vioxx mdl judge eldon fallon previously disclose merck defendant approximately putative class action lawsuit allege economic injury result purchase vioxx case vioxx mdl merck reach resolution approve judge fallon class action vioxx mdl settlement merck pay million resolve properly document claim submit class member approve attorney fee expense approve settlement notice cost certain administrative expense court enter order approve settlement january claim review process recently complete merck defendant lawsuit bring state attorney general state alaska montana utah lawsuit pende state court action allege merck misrepresented safety vioxx seek recovery expenditure vioxx governmentfunde health care program medicaid andor penalty allege consumer fraud act violation trial schedule montana case september trial set alaska case january motion judgment pleading alaska montana case currently pende motion dismiss recently file utah case shareholder lawsuit previously disclose addition vioxx product liability lawsuit putative class action individual lawsuit file merck certain employee allege defendant violate federal security law make alleged material misstatement omission respect cardiovascular safety vioxx vioxx security lawsuit vioxx security lawsuit coordinate multidistrict litigation district court district new jersey judge stanley chesler consolidated purpose august judge chesler grant deny merck motion dismiss fifth amend class action complaint consolidated security class action thing court dismiss certain defendant case dismiss claim base statement voluntary withdrawal vioxx september october remain defendant answer fifth amend class action complaint april plaintiff file motion class certification period september court grant january march plaintiff file motion leave amend complaint add certain allegation expand class period court deny plaintiff motion leave amend complaint expand class period grant plaintiff leave amend complaint add certain allegation exist class period june plaintiff file sixth amend class action complaint class action july defendant answer class action discovery complete closed court grant deny defendant motion summary judgment court grant judgment defendant favor allege misstatement include statement prior march deny motion respect remain statement january company announce reach agreement plaintiff settle class action million plus additional attorney fee expense exchange thing dismissal prejudice class action release claim defendant available fund certain insurance policy merck net cash payment settlement fee approximately million propose settlement cover claim relate vioxx settlement class member purchase merck security october settlement admission wrongdoe settlement agreement defendant continue deny allegation propose settlement include award attorney fee expense subject final court approval february party file stipulation settlement court preliminarily approve february court set final approval hearing june propose settlement resolve individual security lawsuit discuss previously disclose individual security lawsuit file foreign domestic institutional investor consolidate vioxx security lawsuit allegation individual security lawsuit substantially similar allegation vioxx security lawsuit discovery complete action propose settlement class action discuss resolve individual security lawsuit table content individual plaintiff right option join settlement class additional cost merck light propose settlement class action court adjourn previouslyschedule trial date march case consolidate action court schedule conference february discuss pretrial schedule party individual lawsuit settlement reach insurance result previously disclose insurance arbitration company receive insurance proceed approximately million connection settlement class action company director officer insurance coverage applicable vioxx security lawsuit remain state upper limit approximately million dispute insurer availability company director officer insurance coverage claim amount actually recover director officer policy discuss paragraph state upper limit international lawsuit previously disclose addition lawsuit discuss merck name defendant litigation relate vioxx brazil europe collectively vioxx international lawsuit previously disclose january company enter agreement resolve claim relate vioxx canada april company pay approximately million settlement fund agreement approve court canadas province december claim administrator finalize claimant eligibility determination company final payment approximately million settlement fund reserve connection settlement class action remain subject final court approval company establish net reserve million fourth quarter company believe meritorious defense remain vioxx product liability lawsuit vioxx security lawsuit vioxx international lawsuit collectively remain vioxx litigation vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect remain vioxx litigation company establish reserve respect certain vioxx product liability lawsuit company immaterial remain reserve relate previously disclose vioxx investigation nonparticipating state litigation continue company establish liability reserve respect remain vioxx litigation product liability litigation fosamax previously disclose merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case file pende merck federal state court include case seek class action certification damage andor medical monitoring approximately action plaintiff allege thing suffer osteonecrosis jaw onj generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax large majority action subject settlement discuss addition plaintiff approximately action generally allege sustained femur fracture andor bone injury femur fracture association use fosamax case allege onj andor jaw relate injury august judicial panel multidistrict litigation jpml order certain fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax onj mdl coordinated pretrial proceeding december merck reach agreement principle plaintiff steer committee psc fosamax onj mdl resolve pende onj case appeal fosamax onj mdl state table content court aggregate million merck psc subsequently formalize term agreement master settlement agreement onj master settlement agreement execute april condition settlement state federal onj plaintiff agree participate settlement plan merck terminate onj master settlement agreement waive participation requirement agree less funding settlement fund july merck elect proceed onj master settlement agreement reduce funding level participation level approximately merck fully fund onj master settlement agreement escrow agent agreement begin make settlement payment qualify plaintiff approximately nonparticipant case remain settlement complete onj master settlement agreement effect case allege femur fracture discuss case allege femur fracture march merck submit motion transfer jpml seek federal case allege femur fracture consolidate multidistrict litigation coordinate pretrial proceeding motion transfer grant federal case involve allegation femur fracture transfer multidistrict litigation district new jersey femur fracture mdl judge pisano preside femur fracture mdl march time femur fracture mdl reassign judge pisano judge freda wolfson follow judge pisanos retirement bellwether case try date femur fracture mdl glynn merck jury return verdict merck favor addition june femur fracture mdl court grant merck motion judgment matter law glynn case hold plaintiff failure warn claim preempt federal law august femur fracture mdl court enter order require plaintiff femur fracture mdl cause case assert claim femur fracture injury take place prior september dismiss base court preemption decision glynn case pursuant cause order march femur fracture mdl court dismiss prejudice approximately case preemption ground plaintiff approximately case appeal decision court appeal circuit june femur fracture mdl court dismiss prejudice approximately case pende plaintiff appeal preemption rule circuit june judge pisano grant merck summary judgment gaynor merck case find merck update january fosamax label atypical femur fracture adequate matter law merck adequately communicate change plaintiff gaynor appeal judge pisanos decision circuit august merck file motion request judge pisano enter order require plaintiff femur fracture mdl claim fosamax label inadequate proximate cause allege injury cause case dismiss base court preemption decision rule gaynor case november court grant merck motion enter request cause order december approximately case pende femur fracture mdl exclude case dismiss prejudice preemption ground pende appeal case dismiss prejudice pende aforementioned appeal december approximately case allege femur fracture file new jersey state court pending judge jessica mayer middlesex county party select initial group case review fact discovery additional group case review fact discovery select november march respectively group case review fact discovery select merck july december approximately case allege femur fracture file pende california state court petition file seek coordinate femur fracture case file california state court single judge orange county california petition grant judge thierry colaw currently preside coordinate proceeding march court directed group discovery pool case review fact discovery subsequently schedule galper merck case plaintiff select trial galper trial begin february jury return verdict merck favor april plaintiff appeal verdict california appellate court femur fracture trial california schedule hold april currently set include plaintiff table content additionally femur fracture case pende state court discovery ongoing femur fracture mdl state court femur fracture case pende company intend defend lawsuit januviajanumet previously disclose merck defendant product liability lawsuit unite states involve januvia andor janumet december approximately product user claim serve merck alleging generally use januvia andor janumet cause development pancreatic cancer injury complaint file different state federal court claim file consolidated multidistrict litigation proceed district court southern district california call incretinbase therapy product liability litigation mdl mdl include federal lawsuit allege pancreatic cancer use follow medicine januvia janumet byetta victoza product manufacture pharmaceutical company majority claim file mdl file superior court california county los angeles california state court case pende merck state court california state court november mdl grant summary judgment ground preemption claim allege injury pancreatic cancer base ruling november mdl enter final judgment result dismissal pancreatic cancer claim merck relate approximately product user november california state court likewise grant summary judgment preemption ground claim allege injury pancreatic cancer result dismissal pancreatic cancer claim merck relate approximately product user plaintiff appeal mdl preemption ruling expect likewise respect california state court ruling court enter final judgment addition claim note company agree december toll statute limitation approximately additional claim company intend continue defend lawsuit nuvare previously disclose beginning number product liability complaint file jurisdiction assert claim company subsidiary relate nuvare combined hormonal contraceptive vaginal ring plaintiff contend company thing fail adequately design manufacture nuvare fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage injury allegedly sustain product use include alleged death heart attack stroke majority case pende federal multidistrict litigation venue missouri pursuant settlement agreement merck negotiate plaintiff counsel effective june merck pay lump total settlement million resolve case file retainer counsel february plaintiffs approximately case join settlement program file case dismiss prejudice settlement administration process complete dismissal begin second quarter continue rolling basis company certain insurance coverage available currently partially fund company legal fee insurance coverage fund settlement december case pende outside settlement program inclusive case file settlement program close case pende multidistrict litigation subject individual case management order require plaintiff meet discovery evidentiary requirement december plaintiff meeting requirement continue prosecute case propeciaproscar previously disclose merck defendant product liability lawsuit unite states involve propecia andor proscar december approximately lawsuit file plaintiff allege experience persistent sexual effect follow cessation treatment propecia andor table content proscar approximately plaintiff allege propecia proscar cause cause prostate cancer testicular cancer male breast cancer lawsuit file federal court state court new jersey federal lawsuit consolidate pretrial purpose federal multidistrict litigation judge john gleeson eastern district new york matter pende state court new jersey consolidated judge jessica mayer middlesex county addition matter pende state court massachusetts matter pende state court new york company intend defend lawsuit governmental proceeding previously disclose company receive subpoena office inspector general department health human service behalf attorney office district maryland civil division department justice doj request information relate company marketing singulair dulera inhalation aerosol certain marketing activity january present company cooperate government previously disclose company receive civil investigative demand attorney office eastern district pennsylvania request information relate company contract pricing dulera inhalation aerosol certain pharmacy benefit manager medicare plan company cooperate investigation previously disclose company receive letter doj sec seek information activity number country reference foreign corrupt practice act company cooperate agency request believe inquiry broad review pharmaceutical industry practice foreign country previously disclose company advise doj base information receive closed inquiry matter relate company future company receive additional request information doj sec previously disclose company subsidiary china receive continue receive inquiry operation chinese governmental agency inquiry relate matter involve multinational pharmaceutical company chinese entity business company company policy cooperate authority provide response appropriate commercial litigation kdur antitrust litigation previously disclose june january scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upshersmith file abbreviate new drug application anda follow commencement administrative proceed federal trade commission ftc allege anticompetitive effect settlement resolve scheringploughs favor putative class nonclass action suit file behalf direct indirect purchaser kdur scheringplough upshersmith lederle consolidated multidistrict litigation district court district new jersey suit claim violation federal state antitrust law state statutory common law cause action seek unspecified damage april indirect purchaser voluntarily dismiss case march district court grant summary judgment defendant remain lawsuit dismiss matter entirety july circuit court appeal reverse district court grant summary judgment remand case proceeding time circuit uphold december decision district court certify certain direct purchaser plaintiff claim class action august company file petition certiorari supreme court seek review circuit decision june supreme court grant petition vacate judgment circuit remand case consideration light decision ftc actavis inc decision hold socalled reverse payment payment holder pharmaceutical patent party challenge patent connection settlement dispute violate antitrust law table content determine basis rule reason analysis september circuit return case district court proceeding accordance actavis standard april company file motion summary judgment february district court deny company motion summary judgment relate direct purchaser claim concern settlement upshersmith grant company motion summary judgment relate direct purchaser claim concern settlement lederle trial date set sale force litigation previously disclose kelli smith file complaint company united states district court district new jersey behalf putative class female sale representative putative subclass female sale representative child claim discriminatory policy practice selection promotion advancement disparate pay differential treatment hostile work environment retaliation federal state discrimination law november company file motion dismiss class claim plaintiff sought grant leave file amend complaint january plaintiff file amend complaint add additional name plaintiff october court deny company motion dismiss strike class claim premature september plaintiff file additional motion include motion conditional certification equal pay act motion amend pleading seek add erisa constructive discharge claim company subsidiary name defendant motion equitable relief merck file paper opposition motion currently pende court qui tam litigation previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition putative class action lawsuit behalf direct purchaser mmr vaccine charge company misrepresent efficacy mmr vaccine violation federal antitrust law state consumer protection law pende eastern district pennsylvania september court deny merck motion dismiss false claim act suit grant deny motion dismiss thenpende antitrust suit result false claim act suit antitrust suit proceed discovery company intend defend lawsuit merck kgaa litigation january protect longestablished brand rights united states company file lawsuit merck kgaa darmstadt germany kgaa operating emd group united states allege improperly use merck united states kgaa file suit company france united kingdom germany allege breach party coexistence agreement unfair competition andor trademark infringement december paris court instance issue judgment find certain activity company direct france constitute trademark infringement unfair competition activity find infringe date kgaa take step appeal decision january high court issue judgment find company breach coexistence agreement infringe kgaas trademark right result certain activity direct base use word merck promotional information activity note decision find base company use sign merck connection sale product material pharmaceutical business transact decision reflect step litigation process take place number country appeal patent litigation time time generic manufacturer pharmaceutical product file anda food drug administration fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company certain product company product market agreement company currently involve patent infringement litigation united states include cancidas cubicin table content emend injection invanz nasonex noxafil nuvare similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect product acquire acquisition potentially significant intangible asset impairment charge cancidas february patent infringement lawsuit file united states xellia pharmaceuticals aps xellia respect xellias application fda seek prepatent expiry approval market generic version cancidas june district court find xellia infringe company patent order xellias application approve patent expire september include pediatric exclusivity xellia appeal decision appeal hear march august patent infringement lawsuit file united states fresenius kabi usa llc fresenius respect freseniuss application fda seek prepatent expiry approval market generic version cancidas lawsuit automatically stay fda approval freseniuss application december adverse court decision whichever occur early cubicin march patent infringement lawsuit file united states hospira inc hospira respect hospiras application fda seek prepatent expiry approval market generic version cubicin trial hold february december district court find composition patent expire june valid infringe later patent expire september november find invalid hospira appeal find composition patent invalid company crossappeale find later patent invalid november court appeal federal circuit affirm low court decision hospiras application approve june october patent infringement lawsuit file united states strides inc agila specialties private limit stridesagila respect stridesagilas application fda seek prepatent expiry approval market generic version cubicin result hospira decision stridesagilas application approve june july patent infringement lawsuit file united states fresenius respect freseniuss application fda seek prepatent expiry approval market generic version cubicin result hospira decision freseniuss application approve june december patent infringement lawsuit file united states sagent pharmaceuticals inc sagent respect sagent application fda seek prepatent expiry approval market generic version cubicin result hospira decision sagent application approve june december patent infringement lawsuit file united states actavis llc actavis respect actaviss application fda seek prepatent expiry approval market generic version cubicin result hospira decision actaviss application approve june january patent infringement lawsuit file united states reddys laboratories ltd reddys laboratories inc reddy respect reddys application fda seek prepatent expiry approval market generic version cubicin result hospira decision reddys application approve june early district court action teva parenteral medicines inc teva pharmaceuticals usa inc teva pharmaceutical industries ltd collectively teva result settlement teva launch generic version cubicin late december early certain condition event june october agila specialties inc mylan pharmaceuticals inc agilamylan file petition inter parte review ipr united states patent trademark office uspto seek invalidity september november patent april agilamylan withdraw petition ipr exchange company agree narrow issue stridesagila lawsuit reference november fresenius file petition ipr uspto seek invalidity september patent table content uspto grant freseniuss petition ipr september patent ipr hearing hold february july fresenius file petition ipr seek invalidity november patent january uspto grant freseniuss petition ipr november patent emend injection patent infringement lawsuit file united states sandoz inc sandoz respect sandozs application fda seek prepatent expiry approval market generic version emend injection trial lawsuit sandoz hold august court find company patent infringe invalid court order sandozs application approve expiration company patent december sandoz drop appeal court decision june patent infringement lawsuit file united states accord healthcare inc accord healthcare inc intas pharmaceuticals ltd collectively inta respect intass application fda seek prepatent expiry approval market generic version emend injection company agree inta stay lawsuit outcome lawsuit sandoz october following sandoz decision court find company patent infringe invalid court order intass application approve expiration company patent july patent infringement lawsuit file united states fresenius respect freseniuss application fda seek prepatent expiry approval market generic version emend injection january party settle matter term settlement fresenius entitle enter market prepatent expiry certain condition december apotex inc apotex file petition ipr uspto seek invalidity claim compound patent cover emend injection uspto reject apotexs petition june invanz july patent infringement lawsuit file united states hospira respect hospiras application fda seek prepatent expiry approval market generic version invanz lawsuit automatically stay fda approval hospiras application november adverse court decision whichever occur early hospira challenge early patent cover invanz application fda approve patent expire trial matter schedule begin april august patent infringement lawsuit file united states savior lifetec corporation savior respect savior application fda seek prepatent expiry approval market generic version invanz lawsuit automatically stay fda approval savior application november adverse court decision whichever occur early savior challenge early patent cover invanz application fda approve patent expire nasonex july patent infringement lawsuit file united states teva pharmaceuticals usa inc teva pharma respect teva pharmas application fda seek prepatent expiry approval market generic version nasonex lawsuit automatically stay fda approval teva pharmas application november adverse court decision whichever occur early trial matter schedule begin march patent infringement lawsuit file united states amneal pharmaceutical llc amneal respect amneal application fda seek prepatent expiry approval market generic version nasonex lawsuit automatically stay fda approval amneal application august adverse court decision whichever occur early trial matter schedule begin june previous decision issue june hold merck patent teva pharma amneal lawsuit cover mometasone furoate monohydrate valid infringe apotex corps propose product april patent infringement lawsuit file apotex inc apotex corp apotex respect apotexs application fda seek prepatent expiry approval market generic version nasonex allegedly differ generic version previous lawsuit noxafil august company file lawsuit actavis laboratory inc actavis united states respect company application fda seek prepatent expiry approval sell generic version noxafil lawsuit automatically stay fda approval actaviss application december adverse court decision whichever occur early nuvare december company file lawsuit subsidiary allergan united states respect company application fda seek prepatent expiry approval sell generic version table content nuvare trial matter hold january company await court decision september company file lawsuit teva pharma united states respect company application fda seek prepatent expiry approval sell generic version nuvare antipd antibody patent opposition litigation previously disclose ono pharmaceutical ono european patent broadly claim use antipd antibody company immunotherapy keytruda treatment cancer ono previously license commercial right antipd antibody bristol myers squibb bms certain market company believe patent invalid file opposition european patent office epo seek revocation june opposition division epo find claim patent valid company receive opposition division write opinion september company submit substantive appeal february april company company oppose european patent own bms ono believe invalid patent valid broadly claim antipd antibody include keytruda bms ono recently submit request amend claim patent epo allow amendment claim patent long broadly claim antipd antibodie keytruda company file lawsuit seek revocation national version patent july ono bms sue company seek declaration patent infringe marketing keytruda company seek declaration court keytruda infringe patent bms ono notify company request amend claims epo patent intention seek permission court similarly amend national version claim patent long broadly claim antipd antibodie keytruda trial hold july trial issue validity infringement patent hear time court october court issue judgment find patent valid infringe merck appeal judgment february company file lawsuit netherlands seek revocation dutch national version patent bms ono amend claim patent claim patent long broadly claim antipd antibodie keytruda trial validity infringement patent hold january company anticipate decision april december bms ono file lawsuit company france ireland switzerland germany allege infringement patent january bms ono file lawsuit company spain allege infringement patent france bms ono file preliminary relief seek payment damage france case pende hear preliminary relief set february date trial validity infringement irish french swiss spanish national version patent schedule trial concern infringement german version patent currently schedule begin march company continue believe patent invalid company file lawsuit seek revocation patent national courts europe time ono bms file patent infringement action company national courts europe time company launch keytruda national court determine company infringe valid claim patent ono bms entitle monetary damage include royalty future sale keytruda potentially seek injunction prevent company marketing keytruda country uspto grant patent nos ono ono bms patent equivalent patent respectively september bms ono file lawsuit united states allege marketing keytruda company infringe patent bms ono seek prevent stop market keytruda united states trial matter currently schedule begin april company believe patent patent invalid recently ono file lawsuit united states allege market keytruda company table content infringe patent nos patent relate patent company believe patent invalid september company file lawsuit australia seek revocation australian patent equivalent patent march bms ono counterclaim matter allege company manufacture supply keytruda australian market infringe australian patent ono bms similar patent application company closely monitor pende united states japan countries company confident able market keytruda country approve prevent ono bms patent pende application litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial position result operation cash flow individually aggregate legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter previously disclose merck facility oss netherlands inspect province brabant province pursuant dutch hazard major accident decree site environmental permit province issue penalty allege violation regulation govern prevent manage accident hazardous substance government issue fine allege environmental violation oss facility total thousand company subsequently advise criminal investigation initiate base certain issue form basis administrative enforcement action province company intend defend enforcement action result investigation environmental protection agency conduct air compliance evaluation company pharmaceutical manufacturing facility elkton virginia result investigation company recently issue notice noncompliance cause notification relate certain federally enforceable requirement applicable elkton facility company attempt resolve allege violation way settlement defend settlement reach company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government table content cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify accrue cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year equity merck certificate incorporation authorize share common stock share prefer stock capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuance balance december issuance primarily reflect activity sharebase compensation plan noncontrolle interest connection restructure ami merck assume billion par value prefer stock dividend rate annum carry kbi include noncontrolle interest astrazeneca exercise option acquire merck interest azlp note preferred stock obligation retire sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee company issue rsus employee certain company equity method investee addition employee nonemployee director grant option purchase share company common stock fair market value time grant plan approve company shareholder december million share collectively authorize future grant company sharebase compensation plan award settle primarily treasury share table content employee stock option grant purchase share company stock fair market value time grant award generally vest year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus certain psus grant december employee participate dividend basis common share dividend nonforfeitable holder rsus psus issue january dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period generally year subject term applicable award total pretax sharebase compensation cost record million million million respectively relate income tax benefit million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term year value outstanding january grant exercise forfeit outstanding december exercisable december table content additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary begin january active participant merck primary define benefit pension plan accrue pension benefit cash balance formula base age service pay interest transition period january december participant earn great benefit calculate employee legacy final average pay formula cash balance formula year service december participant earn future benefit cash balance formula addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost pension postretirement benefit plan consist follow component pension benefit international postretirement benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement net periodic benefit cost credit change net periodic benefit cost pension postretirement benefit plan year year largely attributable change discount rate affect net amortization table content connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment record pension postretirement benefit plan addition settlement record certain international pension plan obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow pension benefit postretirement international benefit fair value plan asset january actual return plan asset company contribution effect exchange rate change benefit pay settlement fair value plan asset december benefit obligation january service cost interest cost actuarial gain loss benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement benefit obligation december fund status december recognize asset accrue current liability noncurrent liability december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan actuarial gain reflect change discount rate actuarial loss reflect change discount rate plan reflect impact company adoption new retirement plan mortality assumption issue society actuary october decline benefit obligation postretirement benefit result plan amendment primarily reflect change merck retiree medical benefit approve company december change provide beginning merck provide access retiree health insurance coverage supplement governmentsponsore medicare private insurance marketplace new approach allow medicareeligible retiree choose insurance term cost coverage good fit need receive financial support determine merck company subsidy retiree medical coverage table content expect comparable future change support base number factor business condition government action marketplace change general consumer inflation rate information relate fund status select pension plan december follow international pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately company pension investment year end categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total pension plan asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation fix income obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment derivative liability derivative international pension plan asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation corporate obligation fix income obligation real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract plans level investment real estate fund generally value market appraisal underlie investment fund plan level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale balance december international pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation fix income obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment derivative table content company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution expect contribution approximately million pension plan approximately million international pension plan approximately million postretirement benefit plan expect benefit payment expect benefit payment follow international pension postretirement pension benefit benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee follow amount reflect component oci pension plan postretirement international benefit plan year end december net gain loss arise period prior service cost credit arise period net loss amortization include benefit cost prior service credit cost amortization include benefit cost estimate net loss gain prior service cost credit amount amortize aoci net pension postretirement benefit cost million million respectively pension table content plan million million respectively relate pension plan estimate prior service cost credit amount amortize aoci net pension postretirement benefit cost postretirement benefit plan million actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension postretirement benefit plan international pension plan information follow pension postretirement benefit plan international pension plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determine plan basis develop expect rate return plan longterm historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return plan target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate company expect rate return range range pension postretirement benefit plan health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate percentage point change health care cost trend rate follow effect percentage point increase decrease effect total service interest cost component effect benefit obligation saving plan company maintain define contribution saving plan united states company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net income expense net consist year end december interest income interest expense exchange loss equity income affiliate net increase exchange loss drive venezuela second quarter evaluation evolve economic condition venezuela volatility country company determine unlikely outstanding net monetary asset settle official rate vef bolvar fuerte dollar accordingly second quarter company record charge million devalue net monetary asset venezuela include company estimate dollar ultimately collect quarter company record additional exchange loss million aggregate reflect ongoing effect translate transaction net monetary asset consistent second quarter fourth quarter result deterioration economic condition venezuela continue decline transaction settle official rate company begin simadi rate report venezuelan operation company revalue remain net monetary asset simadi rate result additional charge fourth quarter million exchange loss reflect million loss venezuelan currency devaluation february venezuelan government devalue currency vef dollar vef dollar company recognize loss exchange approximately million result remeasurement local monetary asset liability new rate january venezuela designate hyperinflationary result local foreign operation remeasure dollar impact record result operation decline equity income affiliate compare drive primarily termination company relationship azlp june note low equity income azlp partially offset high equity income certain research investment fund net present table include million net charge relate settlement vioxx shareholder class action litigation note expense million contribution investment equity securities merck foundation partially offset million gain sale certain migraine clinical development program note million gain divestiture merck remain ophthalmic business international market note recognition million defer income relate astrazenecas option exercise note net include billion gain divestiture mcc note gain million relate astrazenecas option exercise note million gain divestiture certain ophthalmic product international market note gain million relate divestiture sirna note recognition million defer income relate astrazenecas option exercise partially offset million loss extinguishment debt note million goodwill impairment charge relate company joint venture supera note interest pay million million million table content tax income reconciliation effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise foreign earning tax settlement astrazeneca option exercise sale sirna therapeutics inc american taxpayer relief act impact purchase accounting adjustment include amortization foreign currency devaluation relate venezuela unremitte foreign earning restructure state tax health care reform legislation divestiture merck consumer care include tax effect contingency reserve research credit tax rate change miscellaneous item foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate united states particularly ireland switzerland singapore puerto rico operate tax incentive grant earning indefinitely reinveste yield favorable impact effective tax rate compare statutory rate foreign earning tax rate differential include impact intangible asset impairment charge amortization purchase accounting adjustment restructure cost item present separately represent significant separately disclose pretax cost charge substantial portion item relate jurisdiction low tax rate united states impact record expense item low tax rate jurisdiction unfavorable impact effective tax rate compare statutory rate company effective tax rate reflect impact protect americans tax hike act sign law december extend research credit permanently control foreign corporation lookthrough provision year company effective tax rate reflect impact tax increase prevention act sign law december extend research credit control foreign corporation lookthrough provision year american taxpayer relief act sign law january extend research credit control foreign corporation lookthrough provision year retroactively january december company record entire benefit million financial statement period include date enactment income taxis consist year end december domestic foreign table content taxis income consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation unremitte foreign earning pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize asset defer income taxis discuss note company elect retrospectively early adopt new accounting guidance require defer tax asset liability relate valuation allowance classify noncurrent balance sheet adoption standard follow impact consolidate balance sheet amount previously report current asset reduce million asset increase million accrue current liability reduce million deferred income taxis increase million total asset total liability previously report december reduce million company net operating loss nol carryforward jurisdiction december million defer taxis nol carryforward relate foreign jurisdiction individually significant valuation allowance million establish foreign nol carryforward foreign defer tax asset addition company million defer tax asset relate tax credit carryforward nol carryforward expect fully utilize prior expiry income taxis pay billion billion billion respectively income taxis pay reflect approximately billion taxis pay divestiture mcc tax benefit relate stock option exercise million million million table content reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation balance december amount reflect settlement irs discuss company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease billion month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure item currently discussion internal revenue service irs relate examination company conclude position sustain audit item result unfavorable outcome settlement material adverse impact company financial position liquidity result operation interest penalty associate uncertain tax position amount expense million million benefit million amount reflect beneficial impact tax settlement include discuss liability accrue interest penalty million million december respectively irs currently conduct examination company tax return year irss examination company federal tax return conclude prior issue relate refund claim remain open issue resolve company receive refund approximately million exceed receivable previously record company result tax benefit million addition state foreign tax examination progress significant tax jurisdiction state foreign company income tax return open examination period irs finalize examination scheringplough tax year company unrecognize tax benefit year examination exceed adjustment relate examination period company record net million tax provision benefit company record outofperiod net tax benefit million relate open issue originally raise irs examination issue settle fourth quarter final resolution relate interest owe reach quarter company unrecognized tax benefit relate issue exceed settlement management conclude exclusion benefit material prior year financial statement december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability addition company subsidiary operate puerto rico singapore tax incentive grant begin expire table content earning share calculation earning share share millions follow year end december net income attributable merck inc average common share outstanding common share issuable average common share outstanding assume dilution basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive comprehensive income loss change aoci component follow employee cumulative accumulate benefit translation comprehensive derivative investment plan adjustment income loss balance january net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis relate foreign currency cash flow hedge reclassify aoci sale represent net realize gain loss sale availableforsale investment reclassify aoci income expense net include net amortization prior service cost actuarial gain loss include net periodic benefit cost note include pension plan net loss billion billion december respectively postretirement benefit plan net loss million million december respectively pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december table content segment reporting company operation principally manage product basis comprise operating segment pharmaceutical animal health alliance healthcare service animal health alliance healthcare service segment material separate reporting include table pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sell center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer merck alliance segment primarily include result company relationship astrazeneca termination relationship june companys healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient october company divest consumer care segment note develop manufacture market overthecounter foot care sun care product accounting policy segment describe describe note table content sale company product follow year end december primary care womens health cardiovascular zetia vytorin diabete januvia janumet general medicine women health nuvare implanonnexplanon dulera follistim hospital specialty hepatitis pegintron hiv isentress hospital acute care cubicin cancidas invanz noxafil bridion primaxin immunology remicade simponi oncology keytruda emend temodar diversify brand respiratory singulair nasonex clarinex cozaarhyzaar arcoxia fosamax zocor propecia vaccine gardasilgardasil proquadmmr iivarivax zostavax rotateq pneumovax pharmaceutical total pharmaceutical segment sale segment sale total segment sale sale cubicin represent sale subsequent cubist acquisition date sale cubicin reflect sale japan pursuant previously exist licensing agreement amounts reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate include income expense net amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment animal health alliance healthcare service consumer care divestiture october note alliance segment include revenue company relationship azlp termination june note revenue primarily comprise miscellaneous corporate revenue include revenue hedging activity thirdparty manufacture sale revenue include million receive merck connection sale marketing right saphris note revenue reflect million revenue license pipeline compound table content consolidated revenues geographic area derive follow year end december united states europe middle east africa asia pacific japan latin america reconciliation total segment profit consolidate income taxis follow year end december segment profit pharmaceutical segment segment total segment profit profit unallocate interest income interest expense equity income affiliate depreciation amortization research development amortization purchase accounting adjustment restructure cost gain sale certain migraine clinical development program gain divestiture certain ophthalmic product foreign currency devaluation relate venezuela net charge relate settlement vioxx shareholder class action litigation gain divestiture merck consumer care gain astrazeneca option exercise loss extinguishment debt unallocated net segment profit comprise segment sale standard cost certain operating expense directly incur segment internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization purchase accounting adjustment allocate segment profit primarily comprise miscellaneous corporate profit operate profit relate thirdparty manufacturing sale unallocate net include expense corporate manufacturing cost center goodwill product intangible asset impairment charge gain loss sale business miscellaneous income expense item table content equity income affiliate depreciation amortization include segment profit follow pharmaceutical total year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization property plant equipment net geographic area locate follow december united states europe middle east africa asia pacific latin america japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director shareholders merck inc opinion accompany consolidated balance sheet relate consolidated statement income comprehensive income equity cash flow present fairly material respect financial position merck inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso company management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report item responsibility express opinion financial statement company internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion discuss note consolidated financial statement company change manner classifie defer taxis adoption accounting standard update balance sheet classification defer taxis company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp florham park new jersey february table content supplementary datum select quarterly financial datum contain condense interim financial datum table condense interim financial datum unaudite million share amount sale material production marketing administrative research development restructuring cost income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder sale material production marketing administrative research development restructuring cost income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder amount reflect net charge relate settlement vioxx shareholder class action litigation note foreign exchange loss relate venezuela note gain sale company remain ophthalmic business international market note amount reflect divestiture merck consumer care business october note include billion gain sale amount include loss extinguishment debt note amount include gain sale certain migraine clinical development program note amount include gain sale business note additional year expense health care reform fee amount include foreign exchange loss relate devaluation company net monetary asset venezuela note amount include gain astrazenecas option exercise note amount include tax benefit relate sale sirna therapeutics inc note amount reflect acquisition divestiturerelated cost note impact restructuring action note table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training include financial stewardship training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december table content inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear kenneth frazier robert davis chairman president executive vice president chief executive officer chief financial officer item information table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document page require information compliance section security exchange act incorporate reference discussion head section beneficial ownership report compliance company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer controller code conduct available company website wwwmerckcomaboutcodeofconductpdf company intend disclose future amendment certain provision code conduct waivers code conduct grant executive officer director website business day follow date amendment waiver merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior print copy send charge shareholder request write chief ethic compliance officer merck inc galloping hill road kenilworth require information identification audit committee audit committee financial expert incorporate reference discussion head board meeting committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation table potential payment termination change control include discussion subheading separation change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting shareholder hold require information heading compensation benefit committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting shareholder hold table content item security ownership certain beneficial owner management relate stockholder matter information respect security ownership certain beneficial owner management incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualify plan merck saving plan number number security remain security available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck sharp dohme incentive stock plan merck inc nonemployee directors stock option plan merck inc scheringplough stock incentive plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan exclude share phantom stock defer msd employee deferral program share phantom stock defer merck inc plan defer payment director compensation item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion proposal ratification appointment independent register public accounting firm begin caption preapproval policy service independent register public accounting firm fee service provide independent register public accounting firm company proxy statement annual meeting shareholder hold table content item